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1  Summary 
The translation of mRNAs into proteins is an elaborate and highly regulated process. 
Translational regulation primarily takes place at the level of initiation. During initation 
the eukaryotic initiation factors (eIFs) form a complex that binds to the 5’end of the 
mRNA to scan for a start codon. Once recognized, the ribosome is recruited to the 
mRNA and protein synthesis starts. Initiation of translation can basically occur via two 
distinct  mechanisms,  i.e.  cap-dependent  and  cap-independent  that  is mediated  via 
internal  ribosome  entry  sites  (IRESs).  The  former  is  mediated  by  a  5’cap  structure 
composed of a 7-methylguanylate which is added to every mRNA during transcription 
and  recruits  the  initiation  complex.  IRES-dependent  translation  involves  elements 
within the 5’untranslated region (UTR) of the mRNA that mostly bind IRES trans-acting 
factors (ITAFs) which associate either with the initiation complex or with the ribosome 
itself and consequently allow for internal initiation of translation. 
During tumorigenesis the demand for proteins is increased due to rapid cell growth, 
which  consequently  requires  enhanced  translation.  Many  factors  that  regulate 
translation are overexpressed in tumors. Moreover, signaling pathways that trigger 
translation  or  further  hyperactivated  by  the  surrounding  tumor  microenvironment. 
This  environment  is  largely  generated  by  infiltration  of  immune  cells  such  as 
macrophages that secrete cytokines and other mediators to promote tumorigenesis. 
As the effects of inflammatory conditions on the translation of specific targets are only 
poorly characterized, my study aimed at identifying translationally deregulated targets 
during inflammation-associated tumorigenesis.  
For this purpose, I cocultured MCF7 breast tumor cells with conditioned medium of 
activated  monocyte-derived  U937  macrophages  (CM).  Polysome  profiling  and 
microarray analysis identified 42 targets to be regulated at the level of translation. The 
results were validated by quantitative PCR and one target - early growth response 2 
(EGR2) - was chosen for in depth analysis of the mechanism leading to its enhanced 
translation.  
In  order  to  identify  upstream  signaling  molecules  causing  enhanced  EGR2  protein 
synthesis the cytokine profile of CM was analyzed and the impact of several cytokines 
on EGR2 translation was examined. Preincubation of CM with neutralizing antibodies Summary    2 
 
revealed that lowering interleukin 6 (IL-6) had only little effect, whereas depletion of 
IL-1β significantly reduced EGR2 translation. This finding was corroborated by the fact 
that  treatment  with  recombinant  IL-1β  enhanced  EGR2  translation  to  virtually  the 
same extend as CM. Further experiments revealed that this effect was mediated via 
the p38-MAPK signaling cascade. 
Interestingly,  I  observed  that  the  mTOR  inhibitor  rapamycin,  which  reduces  cap-
dependent translation, specifically stimulated EGR2 translation. This result argued for 
an IRES-dependent mechanism that might account for EGR2 translation. The use of 
bicistronic reporter assays verified this hypothesis. In line with the above mentioned 
results, CM, IL-1β and p38-MAPK induced EGR2-IRES activity.  
Since IRESs commonly require ITAFs to mediate translation initiation, the binding of 
proteins to the 5’UTR was analyzed using mass spectrometry. Among others, several 
previously  described  ITAFs,  such  as  polypyrimidine  tract-binding  protein  (PTB)  and 
heterogeneous nuclear ribonucleoprotein A1 (hnRNP-A1) were identified to directly 
bind to the EGR2-5’UTR. Furthermore, overexpression of hnRNP-A1 enhanced EGR2-
IRES activity whereas a dominant negative form of hnRNP-A1 significantly decreased it, 
thus, showing its importance for EGR2 translation. 
In summary, my data provide evidence that EGR2 expression can be controlled by 
IRES-dependent  translational  regulation,  which  is  responsive  to  an  inflammatory 
environment. The identified mechanism may not be exclusive for one target but might 
be representative for gene expression regulation mechanisms during tumorigenesis. 
This is of special interest for the treatment of cancer patients and development of 
more specific therapies to reduce tumor outcome.  
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2  Zusammenfassung 
Die Translation von mRNAs in Proteine ist ein komplexer Prozess, der aufgrund seines 
hohen Energieverbrauchs strikt kontrolliert wird. Die Regulation findet dabei primär 
auf  Ebene  der  Translationsinitiation  statt.  Während  der  Initiation  bilden  die 
eukaryotischen Initiationsfaktoren (eIFs) einen Komplex, der an das 5’Ende der mRNA 
bindet  und  die  5’untranslatierte  Region  (UTR)  nach  einem  Startcodon  scannt, 
woraufhin  die  ribosomalen  Untereinheiten  an  die  mRNA  rekrutiert  werden.  Die 
Ribosomen  vermitteln  dann  die  eigentliche  Proteinsynthese.  Grundsätzlich  können 
zwei  verschiedene  Arten  der  Initiation  unterschieden  werden  –  die  Cap-abhängige 
sowie die Cap-unabhängige, wobei letztere über sogenannte internal ribosome entry 
sites (IRESs) vermittelt wird. Bei ersterer bindet der Initiationskomplex an die Cap-
Struktur der mRNA, die aus einem N-terminalen 7-Methylguanylat besteht. Bei der 
IRES-vermittelten  Initiation  bindet  der  Initiationskomplex  oder  auch  die  kleine 
ribosomale  Untereinheit  direkt  innerhalb  der  5’UTR  an  die  mRNA,  allerdings  in  3’-
Distanz zur Cap-Struktur.  
Während der Tumorentwicklung kommt es aufgrund des verstärkten Zellwachstums zu 
einem  gesteigerten  Bedarf  an  Proteinen  und  somit  zu  erhöhter  Translation.  Viele 
Faktoren, die die Translation regulieren, werden in Tumoren überexprimiert oder sind 
überaktiv.  Bei  der  Aktivierung  der  entsprechenden  Signalkaskaden  spielt    das 
Tumormilieu  eine  zentrale  Rolle.  Dieses  wird  insbesondere  von  Zellen  des 
Immunsystems  wie  z.B.  Makrophagen  beeinflusst.  Makrophagen  setzen  dabei 
Mediatoren  frei,  welche  das  Tumorwachstum  begünstigen.  Während  tumorigene 
Expressionsveränderungen  auf  Transkriptionsebene  bereits  detailliert  untersucht 
wurden, gibt es nur wenig Information über Translationsveränderungen spezifischer 
Proteine. Deswegen war es das Ziel dieser Studie translationell (de-)regulierte Proteine 
in der entzündungsinduzierten Tumorigenese zu identifizieren.  
Dafür  kokultivierte  ich  MCF7  Brustkrebszellen  mit  konditioniertem  Medium  von 
ausdifferenzierten  U937  Makrophagen  (CM).  Die  Translationsveränderung  in  den 
Tumorzellen wurde mit Hilfe von Polysomenfraktionierungen überprüft. Durch eine 
aufbauende  Mikroarray  Analyse  wurden  42  mRNAs  identifiziert,  die  translationell 
reguliert  wurden.  Die  Ergebnisse  des  Mikroarrays  wurden  anschließend  durch Zusammenfassung    4 
quantitative  PCR  validiert  und  der  Regulationsmechanismus  eines  Targets  –  early 
growth response 2 (EGR2) – im Detail analysiert. 
Dafür untersuchte ich den Einfluss verschiedener im CM vorhandener Zytokine auf die 
EGR2-Translation mittels neutralisierender Antikörper. Es stellte sich heraus, dass die 
Abreicherung von Interleukin 6 (IL-6) die EGR2-Translationsinduktion durch CM nur 
minimal verringerte, wohingegen eine Depletion von IL-1β diese signifikant inhibierte. 
Dieser Befund wurde dadurch unterstützt, dass eine Behandlung mit rekombinantem 
IL-1β  eine  ähnlich  starke  Induktion  der  EGR2-Translation  bewirkte  wie  CM. 
Anschließende  Untersuchungen  ergaben,  dass  dieser  Effekt  durch  die  p38-MAPK 
Signalkaskade vermittelt wurde.  
Desweiteren  wurde  beobachtet,  dass  der  mTOR-Inhibitor  Rapamycin,  der  die  Cap-
abhängige Translation hemmt, ebenfalls zu einer verstärkten EGR2-Translation führte. 
Dies ließ vermuten, dass ein IRES-vermittelter Mechanismus der Translation von EGR2 
zu Grunde lag. Durch die Verwendung von bicistronischen Reporter-Vektoren wurde 
diese Hypothese bestätigt. Außerdem konnte ich beweisen, dass CM, IL-1β und p38-
MAPK  die  EGR2-IRES-Aktivität  in  der  gleichen  Art  beeinflussten  wie  bereits  für  die 
EGR2-Translation mittels Polysomenfraktionierung gezeigt. Da zelluläre IRES-Elemente 
oft  durch  sogenannte  IRES  trans-acting  factors  (ITAFs)  induziert  werden,  wurden 
mittels Massenspektrometrie Proteine identifiziert, die an die 5’UTR von EGR2 binden. 
Unter  anderem  wurden  die  bereits  bekannten  ITAFs  polypyrimidine  tract-binding 
protein (PTB) und heterogeneous nuclear ribonucleoprotein A1 (hnRNP-A1) gefunden. 
Abschließend  konnte bewiesen  werden,  dass die  Überexpression  von hnRNP-A1  zu 
einer Erhöhung der EGR2-IRES-Aktivität führte, wohingegen eine dominant-negative 
Mutante  von  hnRNP-A1  diese  signifikant  inhibierte.  Diese  Ergebnisse  ließen  darauf 
schließen, dass hnRNP-A1 einen entscheidenden Einfluss auf die IRES-abhängige EGR2-
Translation hat. 
Zusammenfassend  konnte  ich  einen  neuen  Translationsregulationsmechanismus  für 
EGR2  identifizieren,  der  durch  ein  entzündliches  Tumormikroenvironment  in 
Tumorzellen induziert wird. Dieser Mechanismus ist möglicherweise auch auf weitere 
translationell regulierte Targets übertragbar. Dies ist von besonderem Interesse, da es 
für  eine  optimale  Behandlung  von  Tumorpatienten  essentiell  ist  die  zu  Grunde 
liegenden Regulationsmechanismen zu verstehen.  Introduction  5 
3  Introduction 
3.1  Translation 
The rapid adaptation of cells to changing conditions is crucial for cell survival. While 
most of the previous research concentrated on the modulation of gene expression via 
transcriptional  changes,  there  has  been  increasing  appreciation  that  likewise  the 
translation of messenger RNAs (mRNAs) to proteins is a highly regulated process. From 
early embryonic development to cell differentiation and apoptosis, translation is used 
to quickly adjust protein levels (1-3). Deregulation of translation results in severe cell 
defects  causing  diverse  maladies  such  as  cancer,  diabetes  or  neurodegenerative 
diseases (4-6). Therefore, understanding translation and its regulation is essential to 
prevent pathological procedures. 
 
3.1.1  Translation initiation 
The  process  of  translation  is  divided  into  three  stages  –  initiation,  elongation  and 
termination  –  each  of  which  requires  a  particular  set  of  conditions  and  factors. 
Initiation  is  the  rate-limiting  step,  which  involves  the  assembly  of  the  translation 
initiation  complex,  including  the  eukaryotic  initiation  factors  (eIFs)  at  the 
5’ untranslated  region  (5’UTR)  of  the  mRNA  to  recruit  the  ribosomes  (7,  8).  The 
ribosomes translate the genetic information encoded by mRNAs into proteins and are 
composed  of  two  subunits  comprising  ribosomal  RNAs  (rRNAs)  and proteins  called 
ribonucleoproteins (RNPs). The small subunit (40S) binds directly to the mRNA to allow 
for reading of the codons whereas the large subunit (60S) recruits the transfer RNAs 
(tRNAs) which are attached to amino acids (9). 
Translation is a cyclic process starting with the formation of the 43S ribosome (Figure 
3-1), which is comprised of eIF2, a heterotrimetic complex that contains an α-, β- and 
γ-domain, and  the  initiating  methionyl tRNA  (tRNAi
Met)  (10).  Only  in  its  GTP-bound 
state the 40S ribosomal subunit joins the complex. Simultaneously, eIF4F composed of 
eIF4E,  eIF4A  and  eIF4G,  attaches  to  the  5’UTR  of  the  mRNA  (11).  In  detail,  eIF4E 
recognizes  and  binds  to  the  cap-structure  consisting  of  a  7-methyl-guanylic  acid 
residue  (m
7G).  eIF4G  serves  as  a  scaffold  protein  for  eIF4E  and  eIF4A.  eIF4A  has Introduction  6 
helicase  activity  to  unwind  secondary  structures  of  the  5’UTR,  thereby  facilitating 
scanning  of  the  mRNA.  Additionally,  eIF3  binds  to  eIF4G  to  finally  recruit  the  43S 
ribosome.  This  initiation  complex  scans  the  mRNA  for  a  start  codon  (AUG)  in  an 
optimal  context  (12).  When  AUG  is  recognized,  eIF2-GTP  is  hydrolyzed  by  eIF5,  a 
GTPase activating protein (GAP), resulting in reduced eIF2 affinity for tRNAi
Met
 and 
partial dissociation of eIF2-GDP from 40S subunits. Furthermore, hydrolysis of eIF5B-
GTP  recruits  the  60S  large  ribosomal  subunit  to  the  complex  (13),  leading  to  the 
binding of tRNAi
Met
 to the peptidyl (P)-site of the ribosome. This results in the complete 
dissociation of the initiation complex, leaving the active 80S ribosome (40S and 60S 
subunit) at the initiation codon. eIF5A promotes formation of the first peptide bond 
and further elongation (14). The inactive eIF2-GDP is recycled to active eIF2-GTP by the 
nucleotide  exchange  factor  eIF2B  to  allow  for  another  round  of  initiation.
 
Figure 3-1: Mechanism of cap-dependent translation 
During  translation  initiation  eIF4E  binds  to  the  m
7G-cap  structure  of  the  mRNA.  eIF4E  is 
additionally associated with the scaffold protein eIF4G that binds the RNA helicase eIF4A to 
unwind secondary structures, thereby facilitating scanning of the genetic code. The attached 
eIF3 recruits the 43S ribosome containing GTP-eIF2, the 40S ribosomal subunit and tRNAi
Met. 
This initiation complex scans the mRNA until the first start codon is detected. When an AUG 
encoding methionine is recognized, eIF2-GTP hydrolyzes to eIF2-GDP resulting in 60S ribosome 
recruitment thereby placing AUG to the P-site of the ribosome. Following dissociation of the 
initiation complex the translation process elongates. Peptide bonding is facilitated via eIF5A. 
eIF2B converts eIF2-GDP to eIF2-GTP. During elongation the amino acid-attached tRNA that is 
complementary to the next codon binds to the A-site. After correct matching is checked by 
eEF1A,  the  tRNA  is  transferred  to  the  P-site  where  a  peptide-bond  is  formed  by  the 
peptidyltransferase of the 60S ribosome and finally the mRNA translocates to the E-site where 
the empty tRNA leaves to ribosome. Abbreviations: A/P/E-site, aminoacyl/peptidyl/exit site; 
eEF,  eukaryotic  elongation  factor;  eIF,  eukaryotic  initiation  factor;  GPD,  guanosine 
diphosphate; GTP, guanosine triphosphate; mRNA, messenger RNA; m
7G, 7-methyl-gyanylic 
acid; ORF, open reading frame; tRNA, transfer RNA; tRNAi
Met
, initiator methionyl tRNA; UTR, 
untranslated region.  Introduction  7 
3.1.2  Translation elongation and termination 
Elongation of translation is a three step mechanism. First, the aminoacyl (A)-site of the 
ribosome is loaded with the appropriate tRNA consistent with the next codon of the 
mRNA. Each tRNA is escorted by the GTP-bound form of eukaryotic elongation factor 
1A (eEF1A-GTP) which controls correct matching of the tRNA to the codon (15). In that 
case, eEF1A-GTP is hydrolyzed to eEF1A-GDP and leaves the ribosome. eEF1B acts as a 
nucleotide exchange factor  to  recycle  GDP to GTP  (16).  Subsequently,  the tRNA  is 
transferred to the P-site. The 28S rRNA that belongs to the 60S ribosomal subunit and 
contains peptidyltransferase activity, attaches the tRNA-associated amino acid to the 
growing peptide chain by forming a peptide bond. Finally, the empty tRNA moves to 
the exit (E)-site of the ribosomes enabling the mRNA to slide to the free P-site to clear 
the A-site for a new tRNA (17). This translocation step is catalyzed by the hydrolysis of 
eEF2-GTP to eEF2-GDP (18) (Figure 3-1).  
When the elongation reaches a stop codon (AUU, UAG, UGA) translation is terminated. 
These codons do not have complementary tRNAs, instead they are recognized by the 
eukaryotic release factor (eRF), which is also GTP-associated. When eRF binds to the A-
site, the peptidyltransferase transfers an H2O molecule to the peptide chain, resulting 
in the release of the newly synthesized protein. eRF-GTP hydrolyzes to eRF-GDP and 
subsequently  the  mRNA  dissociates  from  the  ribosome,  which  disassembles  to  be 
available for a new round of translation (19).  
 
3.1.3  Regulation of translation 
Translation is primarily regulated at the level of initiation rather than elongation or 
termination.  Regulation  takes  place  at  multiple  levels  and  is  directly  linked  to  the 
specificity of the regulated mRNA(s). This includes the modulation of initiation factors 
or ribosomal biogenesis which both affects translation in general. In contrast, RNA-
binding proteins (RBPs), microRNAs (miRNAs) or the mRNA itself via upstream open 
reading frames (uORFs) or structural features such as hairpins or internal ribosome 
entry sites (IRESs) may target a particular mRNA  (Figure 3-2) (20). Introduction  8 
 
Figure 3-2: Elements that influence translation of mRNAs 
The m
7G cap structure at the 5’end and the poly(A) tail at the 3’end are canonical motifs which 
promote translation initiation. Secondary structures block translation, whereas IRES elements 
induce  translation  cap-independently.  Upstream  hairpins  and  open  reading  frames  are 
negative regulators by reducing translation of the main ORF. Yellow ovals symbolize cis-acting 
elements serving as recognition sites for RBPs that can either inhibit or enhance translation. 
miRNAs  mediate  mRNA  stabilization,  decay or  translational  inhibition.  Abbreviations:  IRES, 
internal ribosome entry; m
7G, 7-methyl-gyanylic acid; miRNA, micro RNA; RBP, RNA-binding 
protein; UTR, untranslated region; uORF, upstream open reading frame 
 
 
3.1.3.1  Control of initiation factor activity 
The  phosphatidylinositol-3-kinase  (PI3K)  pathway  is  one  of  the  best  characterized 
pathways regulating global protein translation via phosphorylation of various initiation 
factors  as  well  as  the  ribosome  itself.  Mitogenic  signals  such  as  growth  factors, 
hormones or cytokines activate protein kinase B (PKB/Akt) by phosphatidylinositol-3-
kinase (PI3K) leading to phosphorylation, and thereby activation, of mammalian target 
of rapamycin (mTOR) (21). In its activated state, mTOR phosphorylates the 4E-binding 
protein 1 (4EBP1), thereby releasing eIF4E, which allows for efficient cap-dependent 
translation. Inhibition of mTOR results in a block of 4EBP1 phosphorylation causing 
sequestration of eIF4E and a failure of initiation complex formation. Moreover, mTOR 
phosphorylates p70 S6 kinase (p70
S6K), which in turn phosphorylates the 40S ribosomal 
subunit,  a  critical  step  in  translation  initiation.  p70
S6K  additionally  facilitates  the 
association of eIF4A with eIF4G by promoting the degradation of programmed cell 
death 4 (PDCD4). PDCD4 is known to inhibit the binding of eIF4A to eIF4G (22).  
Another well-established mechanism of broad translation regulation is the control of 
active  eIF2.  Different  kinases  such  as  protein  kinase  R  (PKR),  PRKR  RNA-like 
endoplasmic reticulum kinase (PERK)  or general control nonrepressed 2 (GCN2) are 
known  to  phosphorylate  the  α-subunit  of  eIF2  (23).  Phosphorylated  eIF2  is  fully 
capable  of  forming  an  initiation-competent  43S  ribosome,  but  following  release, Introduction  9 
phosphorylated eIF2-GDP inhibits the guanine nucleotide exchange activity of eIF2B 
which is necessary for the joining of the 40S subunit. This can be reversed by the 
phosphatase growth arrest and DNA-damage-inducible 34 (GADD34). 
 
 
Figure 3-3: Control of initiation factor activity 
Growth  factors  are  capable  of  stimulating  the  PI3K-Akt-mTOR  pathway  leading  to 
phosphorylation  of  p70
S6K  and  4EBP1.  In  the  hypophosphorylated  state,  4EBP1  sequesters 
eIF4E. When hyperphosphorylated by mTOR, eIF4E is released and binds to the cap-structure. 
Phosphorylated p70
S6K induces phosphorylation of the 40S ribosomal subunit and translation is 
initiated. eIF2α is subject to inhibitory phosphorylation by PKR, PERK or GCN2 which can be 
reversed  by  the  phosphatase  GADD34.  MNK1  and  2  are  attached  to  eIF4G  allowing  for 
phosphorylation  and  activation  of  eIF4E.  PDCD4  targets  eIF4A  by  replacing  it  from  eIF4G. 
Abbreviations:  4EBP1,  4E-binding  protein  1;  Akt,  protein  kinase  B;  eIF  eukaryotic  initation 
factor;  GADD34,  growth  arrest  and  DNA-damage-inducible  34;  GCN2,  general  control 
nonrepressed 2; GPD, guanosine diphosphate; GTP, guanosine triphosphate; MNK1/2, MAP 
kinase  interacting  kinase  1/2;  mTOR,  mammalian  target  of  rapamycin;  ORF,  open  reading 
frame; PDCD4, programmed cell death 4; PDK1, pyruvate dehydrogenase kinase 1; PERK, PRKR 
RNA-like  endoplasmic  reticulum  kinase;  PI3K,  phosphatidylinositol-3-kinase;  PKR,  protein 
kinase R; PTEN, phosphatase and tensin homolog; S6K, S6 kinase; VEGF, vascular endothelial 
growth factor; UTR, untranslated region. 
 
 
eIF4E itself is also subject to phosphorylation by MAP kinase interacting kinases 1 and 
2 (MNK1/2). Both are associated with eIF4G which brings them into close proximity 
with  eIF4E,  thereby  facilitating  phosphorylation  of  the  latter.  While  the 
phosphorylation  event  seems  to  be  dispensable  for  normal  development,  it  is 
necessary  for  oncogenic  transformation  by  stimulating  the  translation  of  certain 
oncogenes (see 3.1.4.1) (24). This specificity is not determined by defined sequences, Introduction  10 
but by the increased requirement for eIF4E in the translation of mRNAs with long and 
complex 5' UTRs. The scanning process is severely hampered by secondary structures 
in the 5′ UTR, i.e. a structure with a free-energy of −50 kcal/mol is suﬃcient to impose 
a strong block on scanning (25). Thus, increased availability of eIF4E and associated 
factors  such  as  eIF4A  enhances  the  translation  of  some  tightly  regulated  genes, 
including CyclinD or cMyc (26). 
 
3.1.3.2  Internal ribosome entry sites 
As  described  earlier,  most  mRNAs  utilize  the  cap-structure  to  recruit the  initiation 
complex which facilitates scanning of the sequence for the start condon. However, 
some mRNAs evade the conventional scanning mechanism and at least a subset of eIFs 
by use of IRES elements to recruit the 40S subunit directly to the initiation region, a 
process referred to as internal initiation. IRESs are cis-acting elements within the 5’UTR 
of mRNAs.  
IRES  elements  were  first  described  for  viruses,  as  these  are  able  to  decrease  the 
translation of cellular mRNAs, for example via cleavage of eIF4G which accounts for 
inhibition  of  host  protein  synthesis,  favouring  cap-independent  translation  of  viral 
proteins by internal initiation (27). Up to now a consensus sequence has not been 
identified for IRESs, instead secondary structures are considered to be responsible for 
the  formation  of  an  IRES  element.  These  structures  form  a  scaffold  that  contains 
multiple interaction sites for components of the translation apparatus, e.g. the IRES of 
encephalo myocarditis virus (EMCV) interacts with eIF4G (28), whereas the IRES of 
cricket paralysis virus (CrPV) can directly interact with the 40S ribosome without the 
aid of any initiation factors (29). 
The first eukaryotic IRES was identified in 1991 within the 5’UTR of immunoglobulin 
heavy-chain-binding protein (BiP). Its translation was shown to be sustained during 
poliovirus infection although several initiation factors were cleaved (30). Since this 
initial  discovery,  the  list  of  mRNAs  described  to  contain  IRES  elements  has  been 
growing steadily (see Table 3-1), and in silico analyses estimate that up to 10% of 
cellular mRNAs may contain an IRES element (31). Their protein products are mostly 
involved  in  the  control  of  cell  growth,  proliferation  and  apoptosis  (32).  While  no 
common  structural  features  have  been  found  for  cellular  IRESs,  it  has  been Introduction  11 
hypothesized that cellular IRESs are composed of multiple short modules that include 
structural features as well as sites for RNA-binding proteins and the combined effect of 
these modules promotes internal initiation of translation (32).  
Table 3-1: List of selected eukaryotic IRES containing mRNAs 
Abbreviations: APAF-1, apoptotic peptidase activating factor 1; Bcl-2, B-cell CLL/lymphoma 2; 
c-IAP1, Cellular inhibitor of apoptosis protein 1; cMyc, cellular myc; Dap5, Death-associated 
protein  5;  FGF2,  fibroblast  growth  factor  2;  Hif1α,  hypoxia  inducible  factor  1α;  hnRNP, 
heterogeneous nuclear ribonucleoprotein; IGF-1R, insulin-like growth factor 1 receptor; IGF2, 
insulin-like growth factor 2; IMP2, IGF2 mRNA-binding protein 2; IRF2, interferon regulatory 
factor 2; ITAF, IRES trans-acting factor; La, autoantigen La; NF45, nuclear factor 45; p27
Kip1, 
cyclin-dependent kinase inhibitor p27; PTB, polypyrimidine tract-binding protein; TRAF1, TNF 
receptor-associated factor 1; VEGF, VEGF, vascular endothelial growth factor; XIAP, X-linked 
inhibitor of apoptosis; YB1, Y box binding protein 1. 
 
The activation of cellular IRESs predominantly arises from inhibition of cap-dependent 
translation.  E.g.  when  mTOR  is  inhibited  during  hypoxia,  nutrient  deprivation  or 
mitosis, hypophosphorylated 4EBP1 sequesters eIF4E, which can not bind to the cap-
structure  of  mRNAs  anymore  and  consequently  cap-dependent  translation  is 
repressed. In order to maintain the translation of survival genes, protein synthesis 
switches from cap- to IRES-dependent translation. Therein different mechanisms are 
mRNA  ITAF  Function  Reference 
APAF-1  PTB  apoptosis  (33) 
Bcl2  Dap5  cell survival  (34) 
CyclinD1  hnRNP-A1  cell cycle  (35) 
CyclinT1  PTB  cell cycle  (36) 
c-IAP1  NF45  cell survival  (37) 
cMyc  PTB, YB1, hnRNP-K/-A1  cell survival  (35, 38, 39) 
FGF2  hnRNP-A1  proliferation  (40) 
Hif1α  PTB  cell survival/angiogenesis  (41) 
IGF-1R  PTB  proliferation  (42) 
IGF2  IMP2  proliferation  (43) 
IRF2  PTB  proliferation  (44) 
p27
Kip1  PTB  cell cycle arrest  (45) 
p53  PTB  apoptosis/cell cycle arrest  (46) 
TRAF1  PTB  cell survival  (47) 
VEGF  hnRNP-A1  angiogenesis  (40) 
XIAP  hnRNP-A1/C1/2, La  apoptosis  (48-50) Introduction  12 
known, for example via direct interaction of eIF4G or the 40S ribosome itself with the 
IRES (51).  
However, the mere presence of an IRES within a gene does not necessarily account for 
translation of the mRNA during stress. In fact, IRESs themselves can be subject to 
regulation.  For  example  binding  of  IRES  trans-acting  factors  (ITAFs)  results  in  a 
conformational  change  of  the  mRNA,  facilitating  the  binding  of  initiation  factors 
(Figure  3-4).  Specifically,  the  polypyrimidine  tract-binding  protein  (PTB)  has  been 
proposed to act as a general ITAF that is necessary for the activity of many cellular 
IRESs (52). Additionally, tissue-specific regulation of internal initiation has also been 
reported probably due to differential expression of specific ITAFs (33). 
 
 
Figure 3-4: IRES-dependent initiation of translation 
Stress signals lead to the inhibition of mTOR and consequently repression of cap-dependent 
translation. To maintain the translation of survival genes IRES elements within the 5’UTR of 
mRNAs can internally initiate translation. Initiation factors either bind directly to the IRES or 
via ITAFs which induce conformational changes of the RNA structure. Abbreviations: 4EBP1, 
4E-binding  protein  1;  Bcl2,  B-cell  CLL/lymphoma  2;  eIF,  eukaryotic  initation  factor;  Hif1α, 
hypoxia inducible factor 1α; IRES, internal ribosome entry site; ITAF, IRES trans-acting factor; 
mTOR, mammalian target of rapamycin; ORF, open reading frame; UTR, untranslated region. 
 
 
Strikingly,  ITAFs  are  predominantly  located  in  the  nucleus.  However,  since  these 
proteins are known to shuttle between nucleus and cytoplasm, they can influence 
internal initiation. In line, it was proposed that the “nuclear experience” is important 
for sufficient translation via an IRES. Even though IRES-mediated translation occurs in 
the  cytoplasm,  increasing  evidence  has  shown  that  gene  expression  steps  are 
interconnected from transcription to translation (53).  Introduction  13 
3.1.3.3  RNA-binding proteins 
Many eukaryotic mRNAs contain conserved RNA sequence motifs in their UTRs that 
can be targeted by RBPs. A rough distinction can be made between global and mRNA 
specific  translational  control  mediated by  RBPs.  An  important  positive  regulator of 
global  translation  is  the  poly(A)-binding  protein  (PABP)  that  associates  with  the 
3’poly(A) tail of the mRNA. The stimulatory effect is due to the potential of PABP to 
interact with the 5’UTR-bound eIF4G resulting in a circularization of the mRNA (54) 
which facilitates ribosome recycling. Additionally, eIF4G remains tethered to the mRNA 
and is not needed to be recruited de novo from the free eIF4G pool. Therefore, PABP is 
sometimes denoted as canonical initiation factor. 
However,  RBPs  usually  mediate  inhibition  of  translation  rather  than  activation. 
Negative regulation by protein-RNA interactions in the 5’UTR is rare, as it is assumed 
that RBPs are displaced by the initiation complex during scanning (55). Since the 3’UTR 
of an mRNA is not scanned and - in most cases - relatively long, it offers space for 
regulatory elements. RBPs alter translational efficiency either directly or indirectly by 
bridging proteins on the mRNA. They may also tag mRNAs for rapid deadenylation or 
degradation. Yet, the molecular mechanisms of translational control have only been 
elucidated in few cases. 
RBPs  contain  one  or,  more  often,  multiple  RNA-binding  domains.  Some  well-
characterized RNA-binding domains include RNA-binding domain (RBD), K-homology 
(KH) domain, RGG (Arg-Gly-Gly) box, zinc finger (ZnF) Pumilio/FBF (PUF) domain  and 
AU-rich element domain (ARE) (56). The latter interacts with AU-rich sequences in the 
3’UTR to regulate localization, translation and degradation of mRNAs encoding growth-
response genes, cytokines and cell cycle regulatory proteins (57).  
 
3.1.3.4  MicroRNAs 
MicroRNAs (miRNAs) are small, non-coding RNA strands composed of 21 nucleotides 
that bind to the 3′UTR of their target mRNAs. They control approximately 25% of all 
cellular  mRNAs  at  the  posttranscriptional  level  (58).  Mammalian  miRNA  genes  are 
transcribed by polymerase II from mono- and polycistronic gene clusters resulting in 
large  primary  mRNA  precursors  (pri-miRNAs)  that  contain  hairpin  structures Introduction  14 
harbouring  the  mature  miRNA  as  duplices  (59),  which  are  excised  by  the  RNases 
Drosha and Dicer (60).  
Once processed from its transcript precursor, one strand of the miRNA duplex which is 
complement to the target mRNA is loaded into a protein complex, referred to as RNA-
induced silencing complex (RISC), including members of the Argonaute protein family 
(AGO) and the RNase Dicer. It acts via two distinct mechanisms, which may not be 
exclusive, namely repression of translation or degradation of the target mRNA. The 
degree  of  miRNA-mRNA  complementarity  has  been  considered  to  be  a  key 
determinant  of  the  regulatory  mechanism.  Perfect  complementarity  allows  Ago-
catalyzed cleavage of the mRNA strand, whereas central mismatches exclude cleavage 
and promote repression of mRNA translation (61).  
Repression of translation by miRNAs occurs either by inhibition of translation initiation 
or elongation. The former is caused by the competition between RISC and eIF4E for 
binding to the mRNA cap (62), stimulation of deadenylation of the mRNA tail (63) or a 
blockade of the association of the 60S ribosomal subunit with the 43S preinitiation 
complex (64). Inhibition of elongation involves the promotion of termination by RISCs 
that cause a drop-off of translating ribosomes during elongation (65).  
Once  mRNA  translation  is  inhibited,  the  components  that  are  involved  in  miRNA-
mediated repression concentrate in processing (P)-bodies. These are suggested to be 
sites where mRNAs are sequestered from the translation machinery. Since P-bodies 
contain decapping enzymes and exonucleases, mRNAs are degraded (66). P-bodies are 
closely  related  to  stress  granules,  which  accumulate  in  response  to  various  stress 
conditions (67) and contain nucleases. Eventually, P-bodies and stress granules are 
places to sort translationally inactive mRNAs for storage, reinitiation or degradation 
(58). 
 
3.1.3.5  Upstream open reading frames 
About 45-50% of mammalian genes encode mRNAs that have at least one upstream 
open reading frame (uORF) located in 5’ distance of the main protein coding ORF (68). 
Ribosomes associated with short uORFs (< 30 codons) resume scanning and reinitiation 
at downstream ORFs. With increasing length and structure of the uORF the translation 
of the main ORF is inhibited suggesting a time-dependent mechanism of action (69, Introduction  15 
70). Assumably, this is due to the fact that eIF3 and eIF4G remain weakly associated 
with ribosomes during translation of short uORFs and these factors then promote the 
resumption of scanning leading to reinitiation. This semistable binding is lost after 
enduring scanning of the uORF preventing reinitation (71).  
Another  prominent  mechanism  of  translational  inhibition  involves  the  amino  acid 
sequence of the peptide that is encoded by the uORF which may interact with the 
release  factor  eRF1  to  block  polypeptide  hydrolysis  leading  to  a  blockage  of  the 
ribosome at the stop codon (72). Translation can also be inhibited by the presence of a 
GC-rich  sequence  surrounding  the  stop  codon  of  the  uORF  promoting  ribosome 
dissociation (73). 
 
3.1.4  Translation and disease 
The regulation of translation is a central mechanism to control protein availability in 
the cell. Therefore, aberrant function of components of the translation machinery may 
provoke a variety of human diseases, including cancer and metabolic disorders. 
 
3.1.4.1  Translation and cancer 
Many  cancers  are  caused  by  dysregulation  of  signaling  pathways  controlling  cell 
growth and proliferation. Obviously, these pathways also affect translation. The most 
prominent example is the earlier discussed PI3K-Akt pathway which activates mTOR 
and  is  constitutively  active  in  various  tumor  types  promoting  cellular  growth, 
proliferation  and  survival  (74).  Hyperactivation  of  mTOR  consequently  results  in 
enhanced  translation  via  induction  of  the  downstream  activated  initiation  factors. 
Interestingly, the most affected targets by this mechanism are those that have long 
and highly structured 5’UTRs which are often found in survival genes such as CyclinD1, 
cMyc or ornithine decarboxylase (ODC) (75). This is due to the fact that these mRNAs 
have weaker ability to compete for eIF4F for either ribosome recruitment or mRNA 
unwinding compared to mRNAs with short 5’UTRs. Overexpression of the cap-binding 
protein eIF4E also accounts for this effect and has been observed in multiple tumor 
types (76). Moreover, the phosphorylation status of 4EBP1 is used as a prognostic Introduction  16 
marker in endometrial cancer, especially the hyperphosphorylated, i.e. inhibited form 
of 4EBP1 reflects poor prognosis (77).  
The helicase eIF4A has been reported to be overexpressed in hepatocellular carcinoma 
(78) and primary melanoma cell lines (79). Additionally, it is an important mediator of 
the transforming potential of other initiation factors. In line, the tumor suppressor 
PDCD4 acts via inhibition of eIF4A by replacing it from eIF4G (22) and is lost in certain 
tumors (80). While mTOR inhibitors are already in clinical use for renal cell carcinomas 
(81),  current  approaches  concentrate  on  identifying  more  specific  compounds  to 
target for example PDCD4 or eIF4E (82, 83).  
The development and growth of tumors is challenged by multiple stress situations such 
as hypoxia, nutrient deprivation or apoptosis, which would usually shut down protein 
synthesis  due  to  inhibition  of  mTOR.  Yet,  it  was  observed  that  the  translation  of 
various  survival  genes  is  maintained  via  cap-independent  that  is  IRES-dependent 
translation. This often requires high levels of eIF4G, which binds to many cellular IRESs 
to  recruit  the  ribosome.  Indeed,  eIF4G  together  with  4EBP1  was  found  to  be 
overexpressed in inflammatory breast cancer (84, 85). This induces a hypoxia-activated 
switch  from  cap-dependent  to  IRES-dependent  mRNA  translation  promoting  tumor 
angiogenesis and growth by inducing translation of selective mRNAs such as vascular 
endothelial growth factor (VEGF) and hypoxia inducible factor 1α (Hif1α). Another well 
investigated  target  to  be  IRES-dependently  translated  during  tumorigenesis  is  the 
oncogene cMyc (86). 42% of patients with multiple myeloma have a C to T mutation in 
the cMyc-IRES sequence that results in increased cap-independent translation due to 
enhanced binding of the ITAF hnRNP-K (87) that facilitates IRES-dependent translation. 
Another strategy for tumor promotion is the circumvention of apoptosis via enhanced 
IRES-dependent  translation  of  the  anti-apoptotic  protein  X-linked  inhibitor  of 
apoptosis (XIAP) (88). Increased IRES-dependent translation of XIAP occurs in myeloma 
cells  thereby  contributing  to  radiation  and  drug  resistance  (89).  Consequently,  the 
development of selective inhibitors of translation is of great interest for future tumor 
therapy. 
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3.1.4.2  Translation and inflammation 
Cancer  is  often  associated  with  inflammation  (90).  Monocytes  and  macrophages 
represent an important immune cell population that infiltrates tumors and contributes 
to tumor progression. In invasive breast carcinomas these cells can comprise more 
than 50% of the total tumor mass (91). Among others, they support tumor growth by 
the secretion of various growth factors, such as fibroblast growth factor (FGF2) or 
VEGF  (92).  The  production  of  such  mediators  can  be  regulated  at  multiple  levels, 
including  gene  transcription,  mRNA  translation  and  protein  degradation.  FGF2  and 
VEGF were shown to contain IRES elements in their 5’UTR to induce protein synthesis 
especially under hypoxic conditions to counteract insufficient vascular supply which 
often occurs in growing tumors (93, 94).  
Many other targets of the inflammatory response contain AREs in their 3’UTR and 
provide binding sites for trans-acting factors. Most of these mRNAs are subjected to 
degradation (95). However, some ARE-binding proteins (ARE-BPs) exert their function 
through translational repression or activation of the target mRNA. T cell restricted 
intracellular antigen 1 (TIA-1) binds specifically to the AREs of tumor necrosis factor α 
(TNFα)  and  cyclooxygenase  2  (COX-2)  causing  translational  silencing  (96,  97)  via 
promoting  the  assembly  of  stress  granules.  Another  prominent  ARE-BP  is  Human 
antigen R (HuR). By binding to MAP kinase phosphatase 1 (MKP-1) mRNA to induce its 
translation,  HuR  suppresses  the  function  of  immune  cells.  Moreover,  it  targets 
transforming growth factor β (TGF-β) mRNA, thereby enabling advanced-stage tumor 
cells to escape immune recognition (98). In addition, VEGF contains an ARE in its 3’UTR 
which is targeted by HuR and increases VEGF mRNA stability (99). HuR also binds to the 
5’UTR of certain mRNAs thereby functioning as an ITAF e.g., to induce IRES-dependent 
translation of XIAP (100). 
Thus,  targeting  ARE-BPs  may  provide  a  new  avenue  for  the  development  of 
therapeutic tools for the treatment of chronic inflammatory conditions and related 
cancers. 
 
3.1.4.3  Translation and virus infection 
Viruses  are  dependent  on  the  host´s  translational  apparatus  to  synthesize  their 
proteins. To gain access to the cellular translation machinery and to counteract host Introduction  18 
defense mechanisms, they manipulate cellular signal transduction pathways to control 
the activity of initiation factors. Some viruses impair host translation by removing key 
structural elements in the mRNA, such as the cap, by inactivating eIF4F subunits or by 
manipulating  eIF4F-binding  proteins.  Thus,  synthesis  of  host  defense  molecules 
antagonizing viral replication is prevented (101). Picornavirus, for example, inhibits 
host translation via cleavage of eIF4G, while viral RNA translation is independent of 
eukaryotic initiation factors as they utilize IRES elements in their mRNAs (102). 
Interestingly,  some  viruses  (e.g.,  Herpes  simplex)  enhance  cellular  translation  via 
induction  of  eIF4F  assembly  to  promote  proliferation  of  quiescent  cells  thereby 
promoting reactivation of latent virus infections (103). Furthermore, Herpes simplex 
virus impairs translation of selected host mRNAs by using viral encoded miRNAs, which 
inhibit  the  translation  of  cellular  mRNAs  that  are  required  for  apoptosis  (104). 
Rotaviruses  encode  the  non-structural  protein  3  (NSP3)  that  binds  to  eIF4G  and 
thereby prevents interaction with PABP (105). Moreover, NSP3 associates with the 
3’end of rotavirus mRNA resulting in its circularization. 
As described before, many strategies of regulating translation were firstly identified in 
viruses  (e.g.  IRES-dependent  translation),  and  were  later  shown  to  be  present  in 
eukaryotic cells as well.  
 
3.1.4.4  Translation and neurodegenerative disease 
The importance of translation has also been shown for learning and memory functions 
of  the  mammalian  brain  (106).  Consequently,  it  has  been  implicated  in  neuronal 
diseases.  The  fragile  X  mental  retardation  syndrome  (FMR)  is  a  disorder  which  is 
manifested by mild to severe mental retardation and connective tissue abnormalities. 
It is caused by mutated or weakly expressed FMR protein (FMRP), which is an RNA-
binding protein that normally inhibits the translation of mRNAs whose products have 
critical roles in synaptic plasticity. Recently, it has been shown that FMRP binds to 
eIF4E, thus displacing eIF4G and inhibiting translation (107). FMRP also appears to 
regulate translation by acting on RISC and miRNAs such as miR-125a (108). 
Activation of the eIF2α-inhibiting kinase PKR has been implicated in Alzheimer´s (AD) 
and Huntington´s diseases (HD). PKR was found to bind to the expanded CAG region of 
mutant huntingtin mRNA. CAG repeats form highly stable hairpins that bind to and Introduction  19 
activate  PKR.  Its  activation  increases  in  a  repeat-dependent  manner  (109).  It  was 
hypothesized that activation of PKR may be a common mechanism in the pathology of 
such  trinucleotide  repeat  diseases  and  that  polyglutamine  diseases  may  include  a 
pathological  RNA  mechanism  in  addition  to  the  expression  of  toxic  polyglutamine 
proteins  (110).  In  AD,  activated  PKR  has  been  shown  to  be  associated  with  the 
amyloid β deposits that are thought to be the fundamental cause of the disease (111). 
Subsequent phosphorylation of eIF2α suggests the involvement of a stress response 
mechanism in HD and AD that includes the modulation and/or shutdown of protein 
synthesis followed by the malfunction of affected cells (112). To clarify the exact up-
and downstream events of PKR activation in this context will be of utmost interest. 
 
3.2  Early growth response 2 
Early growth response 2 (EGR2, also known as Krox20) was firstly described in 1988 
and belongs to the family of early growth response genes 1 to 4 (113). Their name 
originates from a study where they were found to be upregulated rapidly after serum 
stimulation  of  quiescent  mouse  fibroblasts  (114).  EGRs  are  transcription  factors 
containing three tandem C2H2-type zinc fingers which bind to GCGGGGCG elements in 
promoter regions to regulate transcription. Although the zinc finger-binding domains 
of  the  EGR  family  members  are  virtually  identical,  the  remaining  domains  differ 
significantly, implying unique functions for each of these transcription factors (115).  
Recently, it has been proven that EGR2 functions as an E3 ligase that sumoylates its 
coregulators (116). Sumoylation is a posttranscriptional modification of proteins by 
small ubiquitin-like modifier (SUMO) and regulates many processes in eukaryotic cells 
such  as  nuclear  transport,  transcription,  chromosome  segregation  and  DNA  repair 
(117). The activity of EGR family members is modulated in part by NGFI-A-binding 
protein 1 and 2 (NAB1/2) and DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 (Ddx20) 
(118-120). Sumoylation of NAB2 by EGR2 modulates its transcriptional activity in a 
negative feedback loop.  
Various functions for EGR2 have been described such as its role in the activation of 
T cell anergy, brain development and cell survival, which will be described in the next 
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3.2.1  EGR2 and T cells 
The activation of T cells is tightly controlled by positive and negative regulatory stimuli. 
One  negative  regulatory  mechanism  is  the  induction  of  T  cell  anergy,  which  is 
characterized  by  a  long-term  hyporesponsiveness  that  occurs  when  T  cells  are 
stimulated  via  their  T  cell  receptors  (TCR)  in  the  absence  of  an  appropriate 
costimulation (121). EGR2 was shown to play a crucial role in this process (Figure 3-5).  
EGR2 is a target gene of nuclear factor of activated T cells (NF-AT), a transcription 
factor that is essential for regulating immune responses (122). NF-AT is activated upon 
calcium influx by dephosphorylation via calcineurin whereupon it translocates into the 
nucleus. Macian et al. proposed that under activating conditions NF-AT cooperates 
with activator protein 1 (AP-1) in order to promote gene expression to enhance T cell 
function,  e.g.  through  production  of  IL-2,  IL-4  or  granulocyte  macrophage  colony-
stimulating factor (GM-CSF) (122). Under suboptimal activating conditions, i.e. in the 
absence of costimulatory molecules (such as CD28), expression of genes dominates 
that are induced by NF-AT alone (123). The expression of EGR2 meets these criteria. 
NF-AT was shown to bind to the promoter region of EGR2 to induce its transcription. 
Thus,  EGR2  represents  a  unique  negative  regulatory  arm  of  TCR-induced  NF-AT 
activation (124).  
The  mechanisms  whereby  EGR2  triggers  T  cell  anergy  are  not  fully  elucidated. 
However,  recent  work  indicates  that  EGR2  induces  the  E3  ligase  Casitas  B-cell 
lymphoma  B  (CBLB)  (124),  which  promotes  the  ubiquitination  and  subsequent 
degradation of key signaling components that activate T cells, such as phospholipase C 
(PLC) and protein kinase C (PKC) (125, 126).  
Additionally,  EGR2  inhibits  IL-2  promoter  activity.  IL-2  is  produced  by  T  cells  in 
response  to  antigenic  or  mitogenic  stimulation  to  induce  their  proliferation  in  an 
autocrine loop and thus, regulates the immune response (127). T cell anergy is induced 
when  IL-2  is  absent.  While  EGR1  has  been  associated  with  T  cell  activation  by 
promoting the upregulation of both IL-2 and the IL-2β receptor (128, 129), EGR2 was 
proposed to counteract this mechanism. Indeed, EGR2 together with EGR3 inhibits 
T cell function by blocking IL-2 production via repression of EGR1 and its co-activator 
NAB2 (130). IL-2 is further repressed via EGR2-dependent transcription of the type III 
histone deacetylase sirtuin 1 (Sirt1), a suppressor of both innate and adoptive immune Introduction  21 
responses (131). Sirt1 subsequently mediates deacetylation and thereby repression of 
the  transcription  factors  AP-1  and  nuclear  factor  kappa-light-chain-enhancer  of 
activated B cells (NF-κB) leading to reduced expression of IL-2 in anergic cells (132). 
Moreover, EGR2 binds to the fasL regulatory element (FLRE) in the promoter region of 
fasL and induces its transcription (133). The cell surface molecule Fas and its ligand 
FasL are required for the activation-induced T cell death to delete T cells that are no 
longer needed (134). EGR2 overexpression alone is sufficient to induce FasL. This effect 
is antagonized by the E3 ubiquitin ligase atrophin interaction protein 2 (AIP2) which 
mediates EGR2 ubiquitination and subsequent degradation, resulting in the inhibition 
of EGR2-driven FasL expression and thereby reducing apoptosis rates (135). 
 
 
Figure 3-5: The role of EGR2 in T cell anergy 
Upon calcium influx NF-AT is dephosphorylated and enters the nucleus to induce transcription 
of EGR2. EGR2 itself is a transcription factor for various T cell anergy-inducing genes, such as 
p21, Sirt1, CBLB and FasL. It also inhibits EGR1, consequently repressing IL-2. IL-2 is a potent 
inducer  of  T  cell  activation.  Upon  secretion  it  binds  to  the  IL-2  receptor  in  an  autocrine 
feedback loop. IL-2 receptor signals via the JAK/Stat pathway and induces transcription of the 
pro-proliferative Cyclins. EGR2 is degraded upon ubiquitination by AIP2. Abbreviations: AIP2, 
atrophin  1  interacting  protein  2;  CBLB,  casitas  B-cell  lymphoma  B;  EGR1/2,  early  growth 
response 1/2; FasL, Fas ligand; IL-2, interleukin 2; JAK, janus kinase; NF-AT, nuclear factor of 
activated  T-cells;  p21,  p21  cyclin-dependent  kinase  inhibitor  1;  Sirt1,  type III  histone 
deacetylase sirtuin 1; Ubi, ubiquitin.  
 
 
Zhu et al. showed that EGR2 controls the proliferation and tolerance of T cells via 
induction  of  p21  cyclin-dependent  kinase  inhibitor  1  (p21
Cip1)  expression  by  direct 
binding to the promoter (136). Loss of EGR2 in T cells causes the lupuslike syndrome in 
mice,  an  autoimmune  disease  that  is  characterized  by  massive  infiltration  of Introduction  22 
inflammatory cells into the kidney and other organs resulting in severe tissue damage. 
These findings again demonstrate the importance of EGR2 for the maintenance of T 
cell  tolerance,  thus, providing  a  potential  target  for the  treatment  of autoimmune 
diseases. 
Another interesting observation is the requirement of EGR2 during positive selection 
of T cells in the thymus. T cells derive from hematopoietic stem cells in the bone 
marrow  and  infiltrate  the  thymus  where  they  differentiate  to  thymocytes.  98%  of 
thymocytes  die  during  development  due  to  selection  processes  ensuring  that  only 
immunocompetent T cells leave the thymus that do not have autoimmune potential. 
One of these steps involves the selection for T cells capable of interacting with major 
histocompatibility  complex  (MHC),  referred  to  as  positive  selection.  Only  those 
thymocytes  that  interact  with  MHC-I  or  MHC-II  will  receive  a  "survival  signal"  for 
example via induction of pro-survival genes. Otherwise they die by apoptosis. EGR2 
induces  the  pro-survival  protein  B-cell  lymphoma  2  (Bcl2)  during  this  process. 
Interestingly,  deletion  of  EGR2  in  thymocytes  impairs  positive  selection,  whereas 
simultaneous overexpression of Bcl2 rescues this defect (137). Moreover, sustained 
EGR2 expression is induced downstream of TCR signalling in precursor natural killer T 
(NKT) cells (138). In line, the absence of EGR2 significantly reduces the percentage and 
absolute number of NKTs at all stages of maturation (139).  
 
3.2.2  EGR2 and myelination 
Myelination  of  nerves  is  mediated  by  axonal  signals  that  trigger  a  program  of 
differentiation in Schwann cells to generate the myelin sheath, one of the most highly 
specialized cellular structures in the body allowing saltatory nerve conduction (140).  
Mutations in the EGR2 gene prevent Schwann cell development and peripheral nerve 
myelination in mice and lead to the development of demyelinating neuropathy (141). 
In humans, a hereditary defect in the EGR2 gene causes congenital hypomyelinating 
neuropathy and type 1 Charcot-Marie-Tooth syndrome (CMT1) (142). CMT1 patients 
suffer  from  severe  weakness,  atrophy  and  sensory  loss  in  distal  muscles  due  to 
segmental demyelination as well as axonal loss (143). 
EGR2  controls  myelin  protein  expression  directly  or  in  conjunction  with  sex 
determining region Y-box 10 (Sox10) (144). In doing so, EGR2 promotes cell survival by Introduction  23 
protecting  cells  from  TGF-β-mediated  cell  death  and  induces  differentiation  via 
enhanced expression of the cell cycle inhibitor cyclin-dependent kinase inhibitor p27 
(p27
Kip1), which is at least in part mediated by the activation of p38 mitogen activated 
protein kinase (p38-MAPK) and inhibition of the JUN N-terminal kinase (JNK) pathway 
(145, 146). Other putative EGR2 target genes include myelin proteins and enzymes 
required for synthesis of normal myelin lipids including myelin protein zero (MPZ), 
which is the most abundant protein component of peripheral myelin and necessary for 
the formation of compact myelin (147, 148).  
 
3.2.3  EGR2 and cell survival  
The role of EGR2 in the regulation of cell survival is poorly understood and studies are 
contradictory. EGR2 was identified to be higher expressed in endometrial cancer cell 
lines  that  overexpressed  the  tumor  suppressor  phosphatase  and  tensin  homolog 
(PTEN)  (149),  suggesting  EGR2  to  be  a  target  of  the  latter.  In  line,  exogenous 
overexpression  of  EGR2  resulted  in  reduced  colony  numbers  of  endometrial  and 
ovarian cancer cell lines while inhibition of EGR2 accelerated cell growth (150). The 
same group identified the pro-apoptotic proteins Bcl2/Adenovirus E1B 19-KD protein-
interacting protein 3-like  (BNIP3L)  and  BCL2-antagonist/killer  (BAK)  as  direct target 
genes of EGR2 leading to the release of cytochrome C, as well as activation of caspase 
9 and 3. EGR2 was also proposed to be a direct target gene of the tumor suppressor 
p53 (151) and compared to normal tissues it was found to be less expressed in a panel 
of tumor cell lines. However, somatic mutations in the EGR2 gene were not observed.  
In  contrast,  EGR2  expression  was  shown  to  be  higher  in  uterine  leiomyomata 
compared with matched healthy myometrial tissues (152). Interestingly, anti-apoptotic 
functions of EGR2 have also been described in osteoclasts (153). Macrophage colony-
stimulating factor (M-CSF) induces MAPK kinase (MEK)-dependent EGR2 expression 
resulting in the upregulation of the pro-survival myeloid cell leukemia 1 (Mcl1), while 
stimulating proteasome-mediated degradation of the pro-apoptotic Bcl-2 interacting 
mediator of cell death (Bim) by the E3 ubiquitin ligase Cbl proto-oncogene (c-Cbl). 
Consequently,  overexpression  of  EGR2  increases  osteoclast  survival.  Contradictory, 
EGR2
+/- preosteoclasts show accelerated proliferation and cell cycle progression, likely 
due to increased colony stimulating factor 1 receptor (cFms) expression, which is a Introduction  24 
macrophage- and monocyte-specific growth factor (154). This suggests a role of EGR2 
in the control of bone mass and a possible target in high-turnover osteoporosis. 
Additionally, EGR2 was identified to be a target gene of the transcription factor SFFV 
proviral  integration  1  (PU.1)  in  macrophages.  In  this  context,  EGR2  facilitates 
differentiation via inhibition of the miR-17-92 cluster that blocks p21
Cip1 and Bim post-
transcriptionally (155). Moreover, EGR2 itself is also targeted by miR-17-92. Since miR-
17-92  is  often  overexpressed  in  peripheral  blood  mononuclear  cells  of  patients 
suffering from acute myeloid leukemia (AML), EGR2 is simultaneously downregulated 
and potentially causes a block in differentation.  
These observations indicate an important role for EGR2 in proliferation, cell survival 
and apoptosis. However, only few studies have been conducted and further research is 
needed to clarify its impact. 
 
 
3.3   Aims of the study 
Deregulated  translation  is  well  appreciated  to  be  a  crucial  component  of  cancer 
development  and  progression.  However,  little  is  known  about  the  corresponding 
stimuli, especially in the context of inflammation-induced tumorigenesis. Therefore, 
the present study aimed at identifying translationally regulated mRNAs in cancer cells 
that are challenged by an inflammatory microenvironment. 
For this purpose, I cocultured breast tumor cells with activated macrophages. In the 
first  part  of  my  work  I  performed  polysome  profiling,  microarray  analysis  and 
subsequent validation to reveal genes that are regulated at the level of translation. 
The  second  part  of  my  project  concentrated  on  the  elucidation  of  the  mechanism 
underlying  the  translational  regulation  of  one  chosen  target.  Therefore,  the 
responsible cytokines and corresponding signaling pathways, as well as contributing 
RNA-binding proteins were investigated. In this context, I specifically focused on the 
mode of translation leading to enhanced protein synthesis of the investigated target.  
This study provides new insights into the modulation of protein expression in cancer 
cells  under  inflammatory  conditions,  thus,  expanding  the  comprehension  of 
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4  Material and Methods 
4.1  Material 
4.1.1  Cells 
All cell lines came from LGC Standards GmbH (Wesel). 
U937 cells 
U937 malignant cells were derived from the pleural effusion of a 37-year-old Caucasian 
man with histiocytic lymphoma 1974 (156). 
MCF7 cells 
MCF7 human breast adenocarcinoma cells were derived from the pleural effusion of a 
69-year-old Caucasian woman with metastatic mammary carcinoma in 1970 (157). 
4.1.2  Bacteria 
Competent  bacteria  strains  were  provided  by  Stratagene  GmbH  (Amsterdam,  The 
Netherlands). XL1-Blue® supercompetent cells were generally used for amplification. 
Ligation reactions were transformed in XL10-Gold® ultracompetent cells.  
4.1.3  Chemicals and reagents 
All  chemicals  were  of  highest  grade  of  purity,  commercially  available  and  usually 
purchased  from  Sigma-Aldrich  (Deisenhofen),  Roth  (Karlsruhe)  or  Merck  Eurolab 
(Darmstadt). Cell culture media, FBS GOLD and supplements came from PAA (Cölbe). 
Special reagents and kits are listed in the table below.  
Table 4-1: Chemicals 
 
Chemical/Kit  Provider 
5’ end tag labeling kit  Axxora (Lörrach) 
5x passive lysis puffer  Promega (Mannheim) 
6x DNA loading dye  Invitrogen (Karlsruhe) 
Absolute™ qPCR SYBR® Green Fluorescein Mix  ABgene (Hamburg) 
Anti-IL-1β  R&D Systems (Wiesbaden) 
Anti-IL-6  R&D Systems (Wiesbaden) Material and Methods  26 
β-Galactosidase enzyme assay system  Promega (Mannheim) 
Biotin maleimide label  Axxora (Lörrach) 
DC protein assay kit  BioRad (Munich) 
D-luciferine  AppliChem (Darmstadt) 
GeneRuler  Invitrogen (Karlsruhe) 
Gylcogen RNA grade  Invitrogen (Karlsruhe) 
HiSpeed Plasmid Maxi Kit  Qiagen (Hilden) 
Human Inflammation Kit (CBA)  BD Biosciences (Heidelberg) 
IgG isotype control (mouse)  R&D Systems (Wiesbaden) 
Maxima First Strand cDNA Synthesis Kit  Fermentas (St. Leon-Rot) 
MEGAclear Kit  Ambion (Darmstadt) 
MEGAshortscript T7 Kit  Ambion (Darmstadt) 
mMESSAGE mMACHINE T7 Kit  Ambion (Darmstadt) 
Nitrocellulose membrane  GE Healthcare (Munich) 
NucleoSpin Gel and PCR Clean-up  MACHEREY-NAGEL (Düren) 
PageRuler Prestained Protein Ladder  Fermentas (St. Leon-Rot) 
Protease inhibitor mix (PIM)  Roche Diagnostics (Grenzach) 
QIAprep Spin Miniprep Kit  Qiagen (Hilden) 
Rapamycin  LC Laboratories (Woburn, USA) 
Recombinant IL-1β  PeproTech (Hamburg) 
Restriction enzymes  New England Biolabs (Frankfurt) 
RNasin Plus RNAse inhibitor  Promega (Mannheim) 
RNeasy Mini Kit  Qiagen (Hilden) 
SB203580  Enzo Life Science (Lörrach) 
T4 DNA ligase  Invitrogen (Karlsruhe) 
Taq DNA Polymerase, recombinant  Invitrogen (Karlsruhe) 
Triton X100  Serva (Heidelberg) Material and Methods  27 
4.1.4  Antibodies 
All antibodies used for Western analysis and according dilutions are listed in Table 4-2.  
Table 4-2: List of Antibodies 
 
Antibody  Provider  Dilution 
Anti-Nucleolin  Santa Cruz Biotechnology (Heidelberg)     
  1:5000 
Anti-phospho-p38  Cell signaling Technology (Frankfurt)  1:1000 
Anti-p38  Cell signaling Technology (Frankfurt)  1:1000 
Anti-HuR  Santa Cruz Biotechnology (Heidelberg)     
  1:3000 
Anti-PTB  Kind gift of Anne Willis (Leicester, UK) (158)  1:1000 
Anti-hnRNP-A1 
Anti-Actin 
Cell signaling Technology (Frankfurt) 
Sigma-Aldrich (Deisenhofen)  
1:1000 
1:3000 
Anti-rabbit/-mouse 
IRDye600/800  Li-COR Biosciences (Bad Homburg)  1:5000 
 
4.1.5  Plasmids 
Used plasmids are listed in Table 4-3 and Table 4-4. All vectors contain an ampicillin 
resistance cassette. 
Table 4-3: List of reporter plasmids 
 
Plasmid  Information  Provider 
pGL3-control 
Contains SV40 promoter upstream of the firefly 
luciferase encoding region 
Promega 
(Mannheim) 
pGL3-basic 
Contains minimal promoter upstream of the 
luciferase encoding region 
Promega 
(Mannheim) 
pGL3-EGR2  Contains EGR2-5’UTR upstream of firefly luciferase  - 
pRF 
Contains SV40 promotor upstream of renilla 
luciferase followed by firefly luciferase 
Addgene 
(Cambride, USA) 
pR-EGR2-F and 
deletion constructs 
pRF with EGR2-5’UTR inserted in the intercistronic 
region of renilla and firefly luciferase 
- 
phpRF 
pRF with hairpin inserted upstream of the renilla 
luciferase to inhibit cap-dependent translation 
(159) 
phpR-EGR2-F 
phpRF with EGR2-5’UTR inserted in the intercistronic 
region of renilla and firefly luciferase 
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AP-1 
pGL2 expression vector containing AP-1-binding site 
of the collagenase promoter region upstream of 
firefly luciferase 
(160) 
Renilla-TK  Transfection control vector containing TK-promoter 
upstream of renilla luciferase 
Promega 
(Mannheim) 
Renilla-SV40 
Transfection control vector containing SV40-
promoter upstream of renilla luciferase 
Promega 
(Mannheim) 
β-Gal-SV40 
Transfection control vector containing SV40-
promoter upstream of β-galactosidase 
Promega 
(Mannheim) 
 
Table 4-4 List of expression plasmids 
 
Plasmid  Information  Provider 
pcDNA3.1 
Expression vector for mammalien cells or in vitro 
transcription containing T7 and CMV promoter 
Invitrogen 
(Darmstadt) 
hnRNP-A1-WT 
Overexpression vector for mammalian cells 
containing wildtype hnRNP-A1 
(161) 
hnRNP-A1-NLS 
Overexpression vector for mammalian cells 
containing dominant-negative hnRNP-A1 (lacks 
nuclear export activity) 
(161) 
pDrive-hrG 
Expression vector for a 300 nucleotide fraction of 
human reverse GAPDH containing T7 promoter 
A. v. Knethen 
 
4.1.6  Oligonucleotides 
Oligonucleotides were purchased from Biomers.net (Ulm). Sequences and according 
annealing temperatures [°C] are presented in Table 4-5 and Table 4-6 .  
Table 4-5: Oligonucleotides for qPCR 
 
Target   Forward primer  Reverse primer   [°C] 
GAPDH  TGCACCACCAACTGCTTAGC  GGCATGGACTGTGGTCATGAG  60 
EGR2  ACGTCGGTGACCATCTTTCCCAAT´  TGCCCATGTAAGTGAAGGTCTGGT  60 
CYP24A1  TTGCCAGCGATAATACGCCTCAGA  AGCAGTGAACCCTGTAGAATGCCT  60 
PLAUR  TGTGGCTCATCAGACATGAGCTGT  TCATCCTTTGGACGCCCTTCTTCA  60 
CBLB  TGAGCCTTGTGGGCATTTGATGTG  TTTCACAACGACAGAAAGGGCAGC  60 
GFRA2  TCTCGGACATCTTCAGGCTTGCTT  TGCAGTTGTCATTCAGGTTGCAGG  60 
VDR  TGAAGCGGAAGGCACTATTCACCT  ACTCCTTCATCATGCCGATGTCCA  60 
AMY1A  AACAGTAACTGGTTCCCGGAAGGT  ACCCGGCCATTACCAAAGTAGTCA  60 Material and Methods  29 
CD44  TCGAAGAAGGTGTGGGCAGAAGAA  ATTTCCTGAGACTTGCTGGCCTCT  60 
EGR3  GCTTTGTTCAGTTCGGATCGCCTT  AAACAATGAGGTGTTTGGGTCGGG  60 
 
Table 4-6: Oligonucleotides for construction of plasmids 
 
Target  Forward primer  Reverse primer  [°C] 
EGR2-5’UTR 
(EcoR1/NcoI) 
GGCCGAATTCGAGCAATTGATTA
ATAGCTCG 
TTAACCATGGTTGCTCCTCGCACA
AC 
69 
EGR2-5’UTR  
(SpeI/NcoI) 
GCACTAGTGAGCAATTGATTAAT
AGCTCGGCG 
TTAACCATGGTTGCTCCTCGCACA
AC 
64 
EGR2-5’UTR 
(HindIII/NcoI) 
CGGCCAAGCTTGAGCAATTGATT
AATAGCTCG 
TTAACCATGGTTGCTCCTCGCACA
AC 
62 
EGR2-5’UTR 
(HindIII/XhoI) 
CGGCCAAGCTTGAGCAATTGATT
AATAGCTCG 
TACTCGAGTTGCTCCTCGCACAAC
C 
62 
EGR2-5’UTR 
(1-166) 
GGCCGAATTCGAGCAATTGATTA
ATAGCTCG 
GCCCATGGATAAAAGTAGCAAAC
AAGTTGCTG 
62 
EGR2-5’UTR 
(167-326) 
GCGAATTCTTCTGTTGATTTTTTTT
TCTTGGTGTGTGT 
TTAACCATGGTTGCTCCTCGCACA
AC 
62 
EGR2-5’UTR 
(1-240) 
GGCCGAATTCGAGCAATTGATTA
ATAGCTCG 
ATCCATGGGGGATGGTATCTCCT
TTTGC 
60.5 
pRF-FL 
ATGACTTCGAAAGTTTATGATCCA
GAACAAAGGAAACGG 
TTACACGGCGATCTTTCCGCCCT  62 
 
4.1.7  Buffers and solutions 
Protein lysis buffer 
Tris/HCl  50 mM  
Sucrose  0.27 M  
Na3VO4  1 mM  
EDTA  1 mM  
EGTA  1 mM  
Na-β-glyercophosphate  10 mM  
NaF  50 mM 
Na-pyrophosphate  5 mM  
Triton-X-100  1% (v/v) 
protease inhibitor   1 tablet/50 mL 
SDS-running buffer 
Tris/HCl  25 mM 
Glycine  192 mM 
SDS  0.7 mM 
® Adjust pH to 8.3 
 
4x SDS sample buffer 
Tris/HCl (pH 6.8)  125 mM 
SDS   2% (w/v) 
Glycerol   20% (v/v) 
Bromphenol blue  0.002% (w/v) 
DTT   5 mM Material and Methods  30 
Sodium dodecyl sulfate (SDS)-polyacrylamide gels 
  12% separating gel  4% stacking gel 
40% Acrylamide/Bis-acrylamide 
(37.5% : 1.0% w/v) 
3 mL  300 µL 
1.5 M Tris/HCl (pH 8.8)  2.5 mL  - 
0.5 M Tris/HCl (pH 6.8)  -  750 µL 
ddH2O  4.4 mL  1.9 mL 
10% (w/v) SDS  100 µL  30 µL 
TEMED  10 µL  5 µL 
10% (w/v) ammonium persulfate  100 µL  50 µL 
 
Blotting buffer 
Tris/HCl   25 mM 
Glycine   192 mM 
Methanol  20% (v/v) 
® Adjust pH to 8.3 
 
TBS-T  (tris buffered saline with Tween) 
Tris/HCl  50 mM 
NaCl   140 mM 
® Adjust pH to 7.4 
Tween-20  0.05% (v/v) 
 
Coomassie blue fixation solution 
Methanol  50% (v/v) 
Acetic acid  10% (v/v) 
Sodium acetate  10 mM 
 
Coomassie blue staining solution 
Acetic acid  10% (v/v) 
SERVA blue G  0.025% (w/v) 
Coomassie blue destaining solution 
Acetic acid  10% (v/v)
   
Polysome buffer  
KCl  140 mM 
Tris/HCl (pH 8.8)  20 mM 
MgCl2  5 mM 
NP-40  0.5% (v/v) 
Heparin  0.5 mg/mL 
DTT  1 mM 
Cycloheximide  100 µg/mL 
RNasin  100 U/mL 
 
RNA incubation buffer 
Tris/HCl (pH 7.4)  10 mM 
KCl  150 mM 
DTT  0.5 mM 
NP-40  0.05% (v/v) 
RNasin  100 U/mL 
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10x MOPS 
MOPS  200 mM 
NaAce  50 mM 
EDTA  10 mM 
® Adjust pH to 7.0 
 
5x RNA sample buffer 
EDTA  4 mM 
Formaldehyde (37%)  7.2% (v/v) 
Glycerol  25% (v/v) 
Formamide (deion.)  31% (v/v) 
10x MOPS  40% (v/v) 
 
Denaturing agarose gel  
Agarose  1% (w/v)   
10x MOPS  10% (v/v) 
Formaldehyde (37%)  2%(v/v) 
Firefly luciferase substrate solution  
Tricine  20 mM 
(MgCO3)4 x Mg(OH)2  1.07 mM 
MgSO4  2.67 mM 
EDTA  100 µM 
DTT  33.3 mM 
ATP  530 µM 
Coenzyme A lithium  0.213 mg/mL 
D-luciferine  470 mM 
® adjust pH to 7.8 
 
Renilla luciferase substrate solution  
NaCl  100 mM 
Tris/HCl, pH 7.5  25 mM 
CaCl2  1 mM 
Coelenterazine  1 µM 
 
4.1.8  Instruments and Software 
Used instruments and software are listed in Table 4-7 and Table 4-8. 
Table 4-7: Instruments 
 
Instruments  Provider 
Agilent 2100 Bioanalyzer  Agilent Technologies (Waldbronn) 
AIDA Image Analyzer  Raytest (Straubenhardt) 
Apollo-8 LB 912 photometer  Berthold Technologies (Bad Wildbad) 
Autoclave HV 85   BPW GmbH (Süssen) 
Bacteria clean bench Hera guard  Heraeus (Hanau) 
Bacteria incubator B5042   Heraeus (Hanau) 
Bacteria incubator Innova®44  New Brunswick Scientific (Nürtingen) 
Biologic LP System  Bio-Rad Laboratories (Munich) 
C1000 Thermal Cycler Realtime PCR  Bio-Rad Laboratories (Munich) 
CASY  Schärfe System (Reutlingen) Material and Methods  32 
Centrifuge 5415 R and 5810 R  Eppendorf (Hamburg) 
LSRII Fortessa  BD Biosciences (Heidelberg) 
Hera cell 150 (Lamina)   Thermo Fisher Scientific (Waltham, USA) 
Hera cell 240 (Incubator)  Thermo Fisher Scientific (Schwerte) 
HBI Auto Densi Flow IIC  UniEquip (Martinsried) 
LabLine Orbit Shaker   Uniequip GmbH (Martinsried) 
Magnetic stirrer Combimag RCH  IKA Labortechnik (Staufen) 
Mastercycler  Eppendorf (Hamburg) 
Microscope Axiovert 200M  Zeiss (Göttingen) 
Milli-Q Synthesis  Millipore (Schwalbach) 
Mini-PROTEAN Tetra Cell  Bio-Rad Laboratories (Munich) 
Mithras LB940 multimode reader  Berthold Technologies (Bad Wildbad) 
NanoDrop ND-1000   Peqlab Biotechnologie (Erlangen) 
Odyssey infrared imaging system  Li-COR Biosciences (Bad Homburg) 
Optima L-90K Ultracentrifuge  Beckman Coulter (Krefeld) 
PowerPac Basic Power Supply  Bio-Rad Laboratories (Munich) 
Rotator  VWR (Darmstadt) 
Sub-Cell® GT electrophoresis system   Bio-Rad Laboratories (Munich) 
SW 40 Ti rotor  Beckman Coulter (Krefeld) 
Thermomixer 5436   Eppendorf (Hamburg) 
Trans-Blot SD blotting machine  Bio-Rad Laboratories (München) 
UV-Transilluminator gel  Raytest (Straubenhardt) 
 
Table 4-8: Software 
 
Software  Provider 
AIDA Image Analyzer  Raytest (Straubenhardt) 
AxioVision Release 4.7  Zeiss (Göttingen) 
BD Biosciences FCAP software  BD Biosciences GmbH (Heidelberg) 
CFX Manager   Bio-Rad Laboratories (Munich) 
CorelDRAW Graphics Suite X4  Corel Corp. (Ottawa, Kanada) 
Endnote  Thomson Reuters (Carlsbad, USA) 
Ingenuity pathway analysis  Ingenuity Systems (Redwood City, USA) 
Lasergene Core Suite  DNASTAR (Madison, USA) Material and Methods  33 
LP Data View  Bio-Rad Laboratories (Munich) 
Mfold  The RNA Institute (New York, USA) (162) 
MikroWin 2000  Berthold Technologies (Bad Wildbad) 
MSOffice 2007  Microsoft Deutschland (Unterschleißheim) 
Chang Bioscience (Castro Valley, CA)  Odyssey 2.1 
 
4.2  Methods 
4.2.1  Cell biology 
4.2.1.1  Cell culture 
MCF7  and  U937  cells  were  maintained  in  Roswell  Park  Memorial  Institute  (RPMI) 
medium supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, 100 
µg/mL streptomycin, and 2 mM L-glutamine. Additionally, U937 medium contained 
1 mM sodium pyruvate. Cells were kept at 37°C in a humidified atmosphere with 5% 
CO2. Cell numbers were determined using the cell counter system Casy
 or Neubauer 
chamber. 
 
4.2.1.2  Generation of conditioned medium from U937 cells 
U937 monocytes (1x10
7 / 25 mL) were exposed to TPA (10 nM) for 48 h. The resulting 
adherent,  activated  monocyte-derived  macrophages  were  trypsinized,  pelleted  and 
washed with PBS. For control purposes undifferentiated monocytes (3x10
6 / 25 mL) 
were incubated with DMSO (0.1%) for 48 h, pelleted by centrifugation and washed 
with PBS. Subsequently, control and differentiated cells were treated equally. For the 
generation of conditioned medium cells were reseeded at a concentration of 2x10
6 / 
5 mL. Cells were allowed to condition medium for 24 h followed by centrifugation, 
sterile filtration (0.45 µm filter) and storage at -80°C until further use. Conditioned 
medium from differentiated cells (CM) was always prepared in parallel to conditioned 
medium from undifferentiated cells (Ctr). All experiments were carried out in U937 
medium.  
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4.2.1.3  Transient transfection 
Transient transfection of cells with over-expression vectors and reporter plasmids was 
performed  using  the  Rotifect  transfection  reagent  (Roth,  Karslruhe).  For  reporter 
analysis 5x10
4 MCF7 cells were seeded in 24-well plates. Antibiotic-free medium was 
changed the next day and cells were transfected with 0.2 µg DNA for 16 h as described 
by the manufacturer. In brief, 0.2 µg DNA and 0.5 µL Rotifect transfection reagent 
were mixed each with 300 µL RPMI medium. The Rotifect mixture was added to the 
DNA mixture, inverted and incubated for 30 min at room temperature (RT). For co-
transfection/overexpression  experiments  0.2  µg  reporter  plasmid  and  0.8  µg 
overexpression  plasmid  were  used  together  with  1  µL  Rotifect.  After  incubation 
60 µL/well of the mixture were added to the cells. Upon 16 h incubation the medium 
was  replaced  with  fresh  complete  cell  culture  medium.  Luciferase  activities  were 
measured 48 h post transfection start. 
 For  RNA  transfection  DNA  constructs  were  linearized  with  BamHI  and  in  vitro 
transcribed using the mMESSAGE mMACHINE T7 Kit (Ambion, Darmstadt) according to 
the manufacturer’s protocol and purified with the MEGAclear Kit (Ambion, Darmstadt). 
0.2  µg  RNA  were  transfected  as  described  for  DNA.  Luciferase  activities  were 
measured 24 h post transfection start. 
 
4.2.1.4  Scratch assay 
2x10
5  MCF7  cells  were  seeded  in  24-well  plates  one  day  prior  to  the  experiment. 
Scratches  were  administered  using  a  10  µL  tip.  After  removal  of  medium  and  cell 
debris, cells were treated and pictures were taken at the indicated time points using an 
Axiovert 200M microscope (Zeiss, Göttingen). 
 
4.2.2  Molecular biology 
4.2.2.1  Polysomal fractionation 
5x10
6 MCF7 cells were seeded in a 15 cm dish one day prior to treatment of the cells. 
After incubation with 100 µg/mL cycloheximide (CHX) for 10 min at 37°C, cells were 
harvested by scraping in 15 mL PBS/CHX (100 µg/mL) and centrifuged in a 50 mL falcon 
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PBS/CHX and transferred to cup. After pelleting again for 30 s, 16000 rpm at 4°C, cells 
were lysed in 750 µL polysome buffer. After pelleting for 5 min, 16000 rpm at 4°C and 
transferring  the  supernatant  to  a  fresh  cup,  600  µL  of  the  cytoplasmic  lysate  was 
layered onto 11 mL of a 10-50% continuous sucrose gradient (in polysome buffer). The 
remaining lysate was stored at -20°C for total RNA. The gradient was centrifuged at 
35000 rpm  for  2  h  at  4°C  without  brake  using  a  SW40  rotor  in  a  Beckman 
ultracentrifuge. Afterwards the gradient was pumped down using Biologic LP system 
(Biorad, Munich). Absorbance was measured at 254 nm and recorded using LP Data 
View software (Biorad, Munich). Finally, 1 mL fractions were collected.  
 
4.2.2.2  RNA isolation 
RNA from sucrose gradients was precipitated with 1/10 volume sodium acetate (3 M), 
1 volume isopropanol and 1 µL glycogen over night at -20°C. After centrifugation for 20 
min,  16000  rpm  at  4°C,  supernatants  were  discarded  and  pellets  were  purified 
together with total RNA samples using the RNeasy MiniKit (Qiagen, Hilden) according 
to  the  manufacturer´s  manual.  RNA  was  eluted  in  30  µL  RNase-free  H2O.  RNA 
concentration was determined using Nanodrop. 
 
4.2.2.3  Denaturing gel-electrophoresis 
For quality control of fractionated RNA, equal volumes were analyzed by denaturing 
agarose gel electrophoresis. For this purpose, 5 µL of each RNA fraction was incubated 
in RNA sample buffer containing 1 µL ethidiumbromide (1:50 of stock solution) per 
20 µL sample volume for 5 min at 65°C. Samples were loaded onto a 1% denaturing 
agarose gel and separated at 80 V for 30 min in 1x MOPS buffer. 
 
4.2.2.4  Reverse transcription and semiquantitative realtime PCR (qPCR) 
250 to 1000 ng RNA were transcribed using the Maxima First Strand cDNA synthesis kit 
(Fermentas, St. Leon Roth) in 10 µL samples containing 2 µL reaction mix and 1 µL 
enzyme mix. Samples were incubated for 10 min at 25°C followed by 15 min at 50°C. 
The reaction was terminated by heating at 85°C for 5 min. The resulting cDNA was 
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purpose 4 µL cDNA were mixed with 0.4 µL Primer (10 pmol/µL each), 10 µL absolute 
qPCR SYBR Green Fluorescent mix (Abgene, Surrey, UK) and filled up to 20 µL with H2O. 
The following thermal cycling program was used: 
 
        50°C      2 min 
Enzyme activation    95C    15 min 
 
Denaturation      95°C    15 s 
Annealing       60°C    30 s 
Extension      72°C     30 s 
 
A melt curve was added to the program to confirm specificity of the reaction: 
Denaturation      95°C    30 s 
Starting temperature   72°C    30 s 
Melting step      72°C to 95°C  05 s 
                 + 0.5°C per cycle 
 
 
4.2.3  Construction of plasmids 
4.2.3.1  Construction of pR-EGR2-F and phpR-EGR2-F 
To assess the IRES activity of EGR2 its 5’UTR and according deletion constructs were 
inserted into pRF (Addgene, Cambridge, USA) and/or phpRF (kind gift of Prof. Anne 
Willis (159)) in between the renilla and firefly open reading frame. 
The 5´UTR of EGR2 was amplified by PCR using 5 µL cDNA of RNA extracted from MCF7 
cells and appropriate primer pairs containing extensions to obtain overhangs of the 
restriction sites for EcoRI (5’) and NcoI (3’) or SpeI (5’) and NcoI (3’) (see Table 4-6). 
For  amplification  of  DNA  fragments,  conventional  PCR  was  performed  using 
recombinant  Taq  DNA  polymerase  (Invitrogen,  Karlsruhe)  according  to  the 
manufacturer’s  protocol.  Briefly,  1.25 µL  forward  and  reverse  primer (10  pmol/µL 
each), 1 µL dNTP mix (10 µM each NTP), 1.5 µL MgCl2, 5 µL 10 x reaction buffer and 
1µL Taq polymerase were mixed with template DNA and filled up with H2O to 50 µL. 
PCRs were performed according to the following profile, while annealing temperature 
was dependent on the used primer pairs.  
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      Lid        94°C 
Initial denaturation    94°C    3 min 
 
Denaturation      94°C    45 s 
Annealing       50°C    30 s 
Extension      72°C     90 s 
 
Denaturation      95°C    45 s 
Annealing       XX°C    30 s 
Extension      72°C     90 s 
 
Final extension    72°C    10 min 
 
 
The  fragment  size  was  verified  by  agarose  gel  electrophoresis.The  vector  pRF  was 
linearized using the restriction enzymes EcoRI and NcoI, whereas phpRF was linearized 
using SpeI and NcoI at 37°C for 4 h. The vectors as well as the PCR product were 
separated on 1% agarose gels using low melting agarose and cut out of the gels. DNA 
was  isolated  from  the  gel  fragments  by  use  of  NucleoSpin  Gel  and  PCR  Clean-up  Kit 
(Macherey & Nagel, Düren). For ligation, the vector (100 ng) and insert were incubated 
with a molar ratio of 1:10 together with 2 µL T4 DNA ligase buffer and 0.5 µL T4 DNA 
ligase in 20 µL sample volume for 1 h at RT. Afterwards 5 µL of ligation mixture was 
transformed into XL10-Gold® ultracompetent bacteria (see 4.2.6.1). Potential positive 
clones were picked, amplified in LB medium and DNA extracted by use of QIAprep Spin 
Miniprep Kit (Qiagen, Hilden) according to the manufacturers manual. Plasmids were 
digested with EcoRI and NcoI or SpeI and NcoI, respectively, to check insertion of the 
fragment. Correct insertion was further verified by sequencing (Seqlab, Göttingen).  
 
4.2.3.2  Construction of pGL3-EGR2 
The  human  EGR2-5’UTR  was  also  cloned  into  the  promoter-less  pGL3-basic  vector 
upstream of the firefly luciferase as described before using HindIII and NcoI resulting in 
pGL3-EGR2. 
5 cycles 
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4.2.3.3  Construction of pcDNA-EGR2 
For in vitro transcription of EGR2-5’UTR it was cloned into the pcDNA3.1(+) vector 
downstream of the T7-promoter using HindIII and XhoI as described before. 
 
4.2.4  Microarray 
4.2.4.1  RNA preparation 
For analysis of the polysomal RNA samples, fractions 6 to 10 from the sucrose gradient 
were  pooled.  Additionally,  total  RNA  was  collected.  RNA  concentrations  were 
determined using the NanoDrop spectrophotometer. RNA quality was assessed using 
2100 Bioanalyzer.  
 
4.2.4.2  Probe labeling, array hybridization and scanning 
The microarray was conducted at the DKFZ Genomics and Proteomics Core Facility 
(Heidelberg).  Therefore,  biotin-labeled  cRNA  samples  for  hybridization  on  Illumina 
Human  Sentrix-12  BeadChip  arrays  were  prepared  according  to  Illumina's 
recommended sample labeling procedure based on the modified Eberwine protocol 
(163). In brief, 250 ng total RNA was used for complementary DNA (cDNA) synthesis, 
followed by an amplification/labeling step (in vitro transcription) to synthesize biotin-
labeled cRNA according to the MessageAmp II aRNA Amplification kit Biotin-16-UTP 
was purchased from Roche Applied Science (Penzber. The cRNA was column purified 
according to TotalPrep RNA Amplification Kit, and eluted in 60 µL of water. Quality of 
cRNA was controlled using the RNA Nano Chip Assay on an Agilent 2100 Bioanalyzer 
and spectrophotometrically quantified with NanoDrop.  
Hybridization was performed at 58°C, in GEX-HCB buffer (Illumina, San Diego, USA) at a 
concentration  of  100  ng  cRNA/µL,  unsealed  in  a  wet  chamber  for  20  h.  Spike-in 
controls for low, medium and highly abundant RNAs were added, as well as mismatch 
control and biotinylation control oligonucleotides. Microarrays were washed twice in 
E1BC buffer (Illumina, San Diego, USA) at room temperature for 5 min. After blocking 
for 5 min in 4 mL of 1% (wt/vol) Blocker Casein in PBS Hammarsten grade array signals 
were developed by 10 min incubation in 2 mL of 1 µg/mL Cy3-streptavidin solution and 
1% blocking solution. After a final wash in E1BC, the arrays were dried and scanned. Material and Methods  39 
Microarray scanning was done using a Beadstation array scanner, setting adjusted to a 
scaling factor of 1 and PMT settings at 430. Data extraction was done for all beads 
individually, and outliers were removed when > 2.5 MAD (median absolute deviation). 
All remaining data points were used for the calculation of the mean average signal for 
a given probe, and standard deviation for each probe was calculated. 
 
4.2.4.3  Data analysis 
Statistical  analysis  of  the  microarray  was  done  by  the  Senckenberg  Institute  of 
Pathology (Faculty of Medicine, Frankfurt) with the statistical computing environment 
R version 2.12 (164). Additional software packages were taken from the Bioconductor 
project  (165).  The  complete  gene  expression  dataset  was  deposited  in  the  Gene 
Expression Omnibus under accession no. GSE35022. 
 
4.2.5  Biochemistry 
4.2.5.1  SDS-PAGE/Western analysis 
For Western analysis, 5x10
5 cells were seeded in 6 cm dishes, treated as indicated, 
scraped in 50 µL protein lysis buffer and snap-frozen in liquid nitrogen. Cell debris was 
pelleted by centrifugation and the supernatant transferred to a new cup. Following 
protein concentration determination (see 4.2.5.2), 50 µg protein were denatured in 
4xSDS  sample  buffer  at  95°C  for  5  min.  Proteins  were  separated  on  12%  SDS-
polyacrylamidgels and transferred onto nitrocellulose membranes. Membranes were 
blocked with 5% BSA in TBS-T for 1h at RT and incubated with the indicated antibodies 
in 5% BSA over night at 4°C (see Table 4-2). Proteins were detected using appropriate 
secondary antibodies (see Table 4-2) and visualized on an Odyssey infrared imaging 
system (Li-COR Biosciences, Bad Homburg).  
 
4.2.5.2  Protein determination 
The protein content of cell lysates was determined using the DC Protein Assay Kit, 
based on the Lowry method (166). Briefly, a standard dilution series of bovine serum 
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as of the standard dilution were pipetted in duplicates into a 96-well plate, 20 µL 
solution  A  followed  by  200  µL  of  solution  B  were  added  to  start  the  colorimetric 
reaction. After 10 min shaking at RT, extinction was measured at 750 nm using the 
Apollo reader. 
 
4.2.5.3  Reporter assay 
MCF7 cells were transiently transfected as described in 4.2.1.3 using Rotifect reagent 
(Roth, Karlsruhe). Cells were lysed in 100 µL passive lysis buffer (Promega, Mannheim) 
and frozen at -80°C. After defreezing on a shaker for 30 min at RT, firefly and renilla 
luciferase were on a Mithras LB 940 luminometer (Berthold, Bad Wildbad). Therefore, 
20  µl  of  the  lysate  were  transferred  in  a  96-well  plate,  50  µL  of  the  appropriate 
reporter assay reagent (see 4.1.7) were added automatically, plates were shaked for 2 
s, and each well measured for 10 s. β-Galactosidase activity was measured using the β-
Galactosidase  Enzyme  Assay  System  (Promega,  Mannheim)  according  to  the 
manufactures manual. To this end 25 µL of the lysate was incubated with 25 µL of 2x 
assay buffer for 1 h at 37°C. After a faint yellow colour has developed, the reaction is 
stopped by use of 75 µL 1 M sodium carbonate. Then the absorbance was read at 420 
nm using Apollo reader. All reporter assays were performed in triplicates. 
 
4.2.5.4  Cytometric Bead Array 
To determine the secretion of TNFα, IL-6, IL-8, IL-1β, IL-10 and IL-12p70 by the U937 
cells,  Ctr  and  CM  were  analyzed  using  the  Cytometric  Bead  Array  (CBA)  Human 
Inflammation  Kit  (BD  Biosciences,  Heidelberg)  according  to  the  manufacturer’s 
manual.  Samples  were  measured  using  the  BD  LSRFortessa  flow  cytometer  and 
analyzed with BD Biosciences FCAP software (BD Biosciences, Heidelberg). 
 
4.2.5.5  In vitro transcription and biotin-labeling  
EGR2-5’UTR (based on NM_000399.3) and human reverse GAPDH were transcribed in 
vitro with the MEGAShortscript Transcription kit (Ambion, Darmstadt) according to the 
manufacturer’s protocol. To this end, 2 µg of plasmid containing a T7 promotor was 
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enzyme mix in a 20 µL reaction for 4 h at 37°C. To remove DNA template, 1 mL TURBO 
DNase was added to the reaction mix and incubated at 37°C for additional 15 min. 
Denaturing  agarose  gel-electrophoresis  (see  4.2.2.3)  was  used  to  verify  the 
transcription. The RNA sample was filled up to 100 µL and extracted using 12.5 µL LiCl 
[4M] and 375 µL EtOH. Reaction was left at -80°C for 1 h, centrifuged at 16000 rpm for 
10 min at 4°C and solved in 20 µL H2O. Afterwards the transcript was biotin-labeled at 
the 5’end using 5’EndTag Nucleic Acid Labeling System (Axxora, Lörrach) according to 
the manufacturer’s instructions. Briefly, 60 µg RNA were incubated with 1 µL universal 
reaction buffer and 1 µL alkaline phosphatase in a 10 µL reaction for 30 min at 37°C. 
Then 2 µL universal reaction buffer, 1 µL ATPγS, 2 µL T4 ligase and 5 µL H2O was added 
and incubated for additional 30 min at 37°C. Finally, 10 µL of biotin-label (12 mg biotin-
maleimide solved in 312 µL anhydrous DMF) were added and incubated for 30 min at 
65°C. Following LiCl extraction as described before, the labeled transcript was ready to 
be used for RNA affinity chromatography. 
 
4.2.5.6  RNA affinity chromatography 
100  µL  streptavidin  agarose  beads  solution  was  washed  5  times  in  1  mL  RNA 
incubation  buffer  by  centrifugation  for  2  min,  3500  rpm  at  4°C.  Then  20  µg  of 
biotinylated RNA were conjugated to the washed streptavidin agarose beads in 500 µL 
incubation buffer at 4°C for 2 h with continuous rotation. Afterwards 500 µg protein 
extract  (lysed  in  incubation  buffer  containing  0.5%  NP-40  and  160  u  RNasin)  were 
added to the beads and incubated for 1 h at 4°C on a rotator followed by 15 min at 
room  temperature.  Beads  were  washed  5  times  with  1  mL  incubation  buffer, 
resuspended  in  30 µL  4xSDS  buffer  and  boiled  for  10  min.  Eluted  proteins  were 
separated by 10% SDS-PAGE. 
 
4.2.5.7  MS analysis 
MS  analysis  was  conducted  by  the  Bioenergetics  Group  (Faculty  of  Medicine, 
Frankfurt).  For  this  purpose,  SDS  gels  were  stained  with  coomassie  blue. 
Corresponding gel-lanes were cut in several slices and proteins were tryptically in-gel 
digested.  Resulting  peptides  were  analyzed  by  nano-ESI-LC-MS/MS  using  an  LTQ-
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end. Obtained mass spectra were searched against the species specific Uniprot protein 
database  (Homo  sapiens)  using  Mascot  2.2  search  engine.  Peptide  matches  were 
filtered by Mascot score cut-off with significance threshold at p < 0.05.  
 
4.2.6  Microbiology 
4.2.6.1  Transformation of bacteria by heat-shock 
Bacteria  were  transformed  with  plasmid  DNA  by  heat-shock.  Therefore,  50  µL  of 
bacteria glycerol stocks were thawed on ice, 50 to 1000 ng plasmid DNA were added 
and incubated for 30 min on ice. After a heat-shock for 45 s at 42°C, bacteria were 
incubated for another 2 min on ice. For initial growth, 450 µL of LB medium were 
added followed by an incubation period for 45 min at 37°C with shaking at 350 rpm. 
500 µL  of  the  bacteria  solution  was  inoculated  on  a  LB  agar  plate  containing  the 
appropriate  antibiotic  (100 µg/mL  ampicillin)  and  incubated  over  night  at  37°C  to 
select positive plasmids carrying bacteria clones.  
 
4.2.6.2  Bacterial culture and plasmid preparation 
For  preparation  of  plasmids  a  single  clone  from  the  LB  agar  plate  was  picked, 
transferred into 3 ml LB medium with the appropriate antibiotic and cultured over 
night at 37°C with shaking (220 rpm). The next day, plasmids were either isolated using 
QIAprep Spin Miniprep Kit (Qiagen, Hilden) according to the manufacturers manual 
and/or the culture was transferred into 300 mL LB medium containing the appropriate 
antibiotic  and  again  shaked  over  night  at  37°C.  Isolation  of  plasmids  was  then 
performed according to the manufacturers protocol using the HiSpeed Plasmid Maxi 
Kit. DNA content was measured with the NanoDrop ND-1000.  
 
4.2.7  Statistical analysis 
Each experiment was performed at least three times. Data are presented as mean 
values  ± SEM.  Statistical  analysis  was  performed  using  Student’s  t-test.  *p < 0.05, 
**p < 0.01, ***p < 0.001 
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5  Results 
5.1   Global analysis of translational changes during inflammation 
To identify targets that are regulated on the level of translation during inflammation, I 
established and characterized an in vitro system to mimic the situation of cells facing 
an inflammatory microenvironment. For this purpose I differentiated U937 monocytes 
to  macrophages  by  treatment  with  10  nM  TPA  for  48  h.  The  supernatant  of 
differentiated  U937  (CM)  and  undifferentiated  U937  (Ctr)  was  collected  after 
additional 24 h and used as treatment for the breast cancer cell line MCF7 (Figure 5-1).  
 
 
Figure 5-1: Scheme of experimental setup 
U937 cells were incubated with 10 nM TPA for 48 h, followed by washing and reseeding to a new dish. 
After additional 24 h CM was harvested and incubated on MCF7 cells. For Ctr, U937 cells were left 
untreated. 
 
5.1.1  Characterization of conditioned medium 
First,  I  wanted  to  investigate  the  characteristics  of  CM  and  Ctr  with  respect  to 
inflammation and tumorigenesis and their functional consequences on MCF7 cells.  
 
5.1.1.1  CM contains various pro-inflammatory cytokines 
To verify that CM generates an inflammatory environment, I tested the abundance of 
various cytokines using CBA analysis. For this purpose CM and Ctr were generated as 
described before and stained with CBA inflammation kit for different cytokines that 
were measured by FACS. TNFα, IL-6, IL-8, IL-1β and IL-10 were significantly upregulated 
in CM compared to Ctr (Figure 5-2). However, the mean concentrations of TNFα (9.24 
± 2.28 pg/mL) and IL-6 (12.34 ± 3.57 pg/mL) remained at rather low concentrations in 
CM, whereas IL-8 (19.95 ± 21.64 ng/mL), IL-1β (91.73 ± 16.57 pg/mL) and IL-10 (204.00 
± 26.97 pg/mL) reached physiological relevant concentrations. In contrast, IL-12p70 
was hardly detectable in Ctr as well as CM (0.84 ± 0.50 pg/mL). Results                                                                                                                                           44 
 
Figure 5-2: CBA of CM vs. Ctr 
To  determine  the  secretion  of  TNFα,  IL-6,  IL-8,  IL-1β,  IL-10  and  IL-12p70  by  undifferentiated  and 
differentiated  U937  cells,  Ctr  and  CM  were  analyzed  using  CBA.  Samples  were  measured  by  FACS. 
Horizontal bar represents mean of the different samples. (n > 3, **p < 0.01) 
 
These  data  provide  evidence,  that  CM  indeed  generates  an  inflammatory 
microenvironment by the secretion of various proinflammatory cytokines and can be 
used for further experiments. 
 
5.1.1.2  CM induces AP-1 transactivation and tumor cell migration 
To determine whether CM induces tumorigenic effects in MCF7 cells, I measured the 
activity of the transformation marker AP-1 using a reporter plasmid that contains an 
AP-1-binding site of the collagenase promoter region (160). For this purpose, MCF7 
cells  were  transfected  with  the  reporter  plasmid  together  with  a  renilla  luciferase 
containing  vector  as  transfection  control  and  treated  for  24  h  with  normal  RPMI 
medium  (NM),  Ctr  or  CM,  respectively.  As  depicted  in  Figure  5-3,  CM  induced  a 
significant transactivation of AP-1 up to 4.5 ± 0.40 fold in comparison to NM, whereas 
Ctr had no effect.  
As an increase in AP-1 activity indicates a pro-tumorigenic effect of CM on MCF7 cells, I 
additionally wanted to test its impact on another functional endpoint, i.e. tumor cell 
migration using scratch wound healing assays. For this purpose cells were seeded in 
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confluent cells. Migration of MCF7 was markedly increased after 4 h treatment with 
CM, whereas Ctr did not influence the migration compared to NM. 
 
 
Figure 5-3: CM has pro-tumorigenic potential 
(A) MCF7 cells were co-transfected with an AP-1 firefly reporter and a renilla luciferase plasmid 
16 h prior to treatment with NM, Ctr or CM for 24 h. AP-1 activity was normalized to renilla 
luciferase and presented relative to NM treated cells. All data are given as means ± SEM (n > 3, 
***p < 0.001). (B) MCF7 cells were subjected to a scratch wound assay. After administration of 
the scratch, medium was changed to NM, Ctr or CM. Wound closure was examined after 4 h. 
 
In  summary,  enhanced  AP-1  transactivation  as  well  as  the  increased  migration  is 
indicative for the induction of a tumor-promoting programm in MCF7 cells that was 
provoked after treatment with CM, which generates a proinflammatory environment. 
 
5.1.2  Establishment of polysomal fractionation 
As the aim of my study was to identify proteins that are regulated at the translational 
level,  I  established  the  method  of  polysomal  fractionation.  For  this  technique 
cytoplasmic lysates were generated and layered on a sucrose gradient. Subsequent 
ultracentrifugation  led  to  sedimentation  of  mRNAs  according  to  their  ribosome 
occupancy. 
The UV profile of cellular lysates that were subjected to polysomal fractionation as 
shown  in  Figure  5-4  started  with  a  high  peak  that  contained  small  RNAs  such  as 
transfer  RNAs  (tRNAs)  or  small  nucleolar  RNAs  (snoRNAs)  and  ribonucleoproteins 
(RNPs)  leading  to  high  absorption.  The  profile  then  dropped  and  peaks  could  be 
detected for the 40S, 60S and 80S ribosomes as indicated. Then the profile dropped 
again and changed over to smoothly rising peaks representing enhanced ribosome 
loading (polysomes). The ribosome distribution was further confirmed by visualizing 
the 28S rRNA which belongs to the large ribosomal subunit and the 18S rRNA that is 
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and subjected to denaturing agarose gel-electrophoresis. The distribution of the two 
rRNAs fitted very well to the UV profile, thus confirming the validity of using polysomal 
fraction for the investigation of translational changes. 
 
 
Figure 5-4: UV profile of MCF7 cells after polysomal fractionation 
MCF7 cells were subjected to polysomal fractionation and the absorbance was measured at 254 nm. 
RNA was isolated from single fractions and equal volumes were analyzed using denaturing agarose gel-
electrophoresis. 28S and 18S rRNAs were visualized with ethidiumbromide. 
 
5.1.3  Microarray 
For identification of genes that are regulated on polysome level during inflammation, I 
conducted  a  microarray  in  cooperation  with  the  Genomics  and  Proteomics  Core 
Facility  (DKFZ,  Heidelberg)  and  the  Senckenberg  Institute  of  Pathology  (Faculty  of 
Medicine, Frankfurt). For this purpose MCF7 cells were treated for 4 h with CM or Ctr, 
followed by polysomal fractionation. Fractions 6 to 10 were pooled and subjected to 
microarray analysis by use of a whole genome BeadChip array (Illumina). In parallel, 
microarray analysis of total mRNA was performed. 
 
5.1.3.1  Microarray results of total changes 
Initially, I analyzed changes of total mRNA expression in response to CM. 144 genes 
were  found  to  be  more  than  2  fold  upregulated  on  total  mRNA  level  (Table  5-1), 
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Table 5-1: List of genes that were more than 2 fold upregulated on total level 
Gene  Fold change  Gene  Fold change  Gene  Fold change 
PHLDA1  18,8  LOC649095  3,2  MAP2K3  2,5 
EGR1  14,7  FLRT3  3,2  RPL7L1  2,5 
SERPINE1  13,0  CD83  3,1  SDCBP  2,4 
IL24  12,0  NFKBIA  3,1  VCL  2,4 
F2RL1  8,6  TMEM2  3,1  ZC3H12A  2,4 
TNFRSF21  8,6  IL4R  3,1  ABCC3  2,4 
IL8  8,2  SOX9  3,1  HPS3  2,4 
KCNF1  8,2  PMEPA1  3,0  FURIN  2,4 
RASD1  7,9  BHLHB2  3,0  GJB2  2,4 
IL8  7,7  ANKRD57  3,0  KRT16  2,4 
ZNF365  7,3  SERPINB8  3,0  PTPRE  2,3 
DUSP5  7,1  PLEK2  3,0  LOC728014  2,3 
TNFRSF11B  7,0  THBS1  2,9  MYADM  2,3 
IL24  7,0  LIF  2,9  ATP1B1  2,3 
MALL  6,7  ZNF275  2,9  PLAUR  2,3 
TM4SF1  6,6  VCL  2,9  IRF2BP2  2,3 
ITGA2  6,5  JUNB  2,8  TMEM158  2,3 
ERRFI1  6,5  ZFP36L2  2,8  ITGB2  2,2 
STAMBPL1  5,9  CEBPB  2,8  CXCR4  2,2 
LRRC8C  5,9  SLC4A7  2,8  DKFZP761P0423  2,2 
SPRY4  5,7  PMEPA1  2,8  DSG2  2,2 
F2RL1  5,6  DOK7  2,8  FLJ13236  2,2 
MAFF  5,6  SPHK1  2,8  DDB1  2,2 
IL1RL1  5,3  TRIB1  2,8  SDCCAG1  2,2 
DUSP4  5,0  TNFRSF12A  2,7  SPRED2  2,2 
KIAA1199  4,7  PRPF40A  2,7  ZYX  2,2 
CCL2  4,6  CCNA1  2,7  RBMS1  2,2 
NUAK2  4,6  HBEGF  2,7  RBMS1  2,2 
FOSL1  4,2  NUAK2  2,7  MPZL2  2,2 
LTB  4,0  ARNT2  2,7  BAZ1A  2,1 
PMEPA1  4,0  IFNGR2  2,7  QPCT  2,1 
FHL2  3,9  ALDH1A3  2,7  NOL6  2,1 
TNFAIP8  3,9  OSMR  2,6  TNFRSF10A  2,1 
ELL2  3,9  KRT80  2,6  LHFPL2  2,1 
STX11  3,7  PALLD  2,6  ZSWIM4  2,1 
IER3  3,7  LONRF2  2,6  MGC3020  2,1 
EGFR  3,6  IGF2BP2  2,6  EIF2C2  2,1 
SMAD3  3,6  BIRC3  2,6  JUN  2,1 
CLDN1  3,6  RELB  2,6  NDE1  2,1 
ITGAV  3,5  MCL1  2,6  GNL3L  2,1 
ZSWIM4  3,5  ZYX  2,5  ADORA2A  2,1 
FOXO1  3,4  ETS2  2,5  ZFP36  2,1 
ATF3  3,4  FRMD6  2,5  CSNK1E  2,1 
SH3TC1  3,4  MYEOV  2,5  ARTN  2,0 
TNF  3,4  TNFAIP3  2,5  ALDH1A3  2,0 
SERPINB8  3,3  RGS16  2,5  HS.60257  2,0 
FHL2  3,3  CCRN4L  2,5  FOXC1  2,0 
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Table 5-2: List of genes that were more than 2 fold downregulated 
Gene  Fold change  Gene  Fold change  Gene  Fold change 
ZNF823  -2,0  PPP2R3C  -2,3  RTN4RL1  -2,7 
TRERF1  -2,1  HS.193406  -2,4  ID2  -3,3 
CKAP2L  -2,1  AIFM2  -2,5  FAM46B  -4,6 
CDC42EP4  -2,2  RPRM  -2,6  CYP1A1  -4,6 
SEMA3F  -2,3 
 
To elucidate molecular mechanisms and pathways that are induced in MCF7 cells upon 
treatment with CM, the complete target list was subjected to pathway analysis using 
Ingenuity software. Table 5-3 provides an overview of the obtained results with the 
amount  of  associated  molecules.  Within  the  associated  network  functions 
inflammatory  and  cancer  responses  were  enriched.  Similarly,  cancer  emerged  as a 
disease relevant function and molecular changes were also indicative of tumorigenic 
changes (i.e. cell growth, proliferation and cellular movement). The data also provided 
evidence, that IL-6, TNFR2 and IL-10 signaling pathways were likely to be activated in 
our setting. 
 
Table 5-3: Results of Ingenuity pathway analysis of total changes 
Associated network functions  Molecules 
Cell death, proliferation, inflammatory response  39 
Inflammatory response and disease  32 
Cancer, cell cycle  17 
Molecular and cellular functions   
Cell death  53 
Cellular growth and proliferation  56 
Cellular movement  34 
Diseases and disorders   
Cancer  65 
Reproductive system disease  43 
Dermatological diseases  21 
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Signaling pathways  Molecules 
IL-6 signaling  9/98 
TNFR2 signaling  6/32 
IL-10 signaling  7/72 
 
These  results  support  the  concept  that  TPA-activated  U937  monocyte-derived 
macrophages induce a pro-tumorigenic and inflammatory response in MCF7 cells. 
 
5.1.3.2  Microarray results of polysomal changes 
For  identification  of  those  mRNAs  that  are  regulated  at  the  level  of  translation,  I 
compared the changes in mRNA abundance in the polysomal as well as in the total 
RNA.  
The targets that significantly changed in the polysome-associated portion but not on 
total level were considered as translationally regulated. Using these criteria 42 genes 
were  identified  (Table  5-4).  Specifically,  25  genes  were  translationally  upregulated, 
whereas 17 genes were downregulated. Among these mRNAs early growth response 2 
(EGR2), plasminogen activator urokinase receptor (PLAUR), mitogen-activated protein 
kinase kinase kinase 5 (MAP3K5), GDNF family receptor alpha 2 (GFRA2) and Cas-Br-M 
(murine) ecotropic retroviral transforming sequence b (CBLB) showed the strongest 
translational induction (2.5 to 7.0 fold), while aquaporin 11 (AQP11), FYVE, RhoGEF 
and PH domain containing 3 (FGD3), ring finger protein 214 (RNF214), Fanconi anemia, 
complementation  group  E  (FANCE)  and  leucine  rich  repeat  containing  20  (LRRC20) 
displayed the strongest translational repression (-2.2 and -2.7 fold). 
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Table 5-4: Heatmap of translationally regulated genes 
 
 
5.1.3.3  Validation of microarray results 
After accomplishing the microarray, the first task was to validate the obtained results 
by semiquantitative realtime PCR (qPCR). For this purpose targets were selected based 
on their magnitude of regulation but also by considering their functional relevance. I 
performed again polysomal fractionation with MCF7 cells that were treated for 4 h 
with CM or Ctr, respectively, and compared the changes in pooled polysomal fractions 
6 to 10 to the changes on total RNA level by use of qPCR with primers against selected 
targets.  Results                                                                                                                                           51 
 
Figure 5-5: Comparison of poly vs. total change 
MCF7 cells were treated with CM or Ctr for 4 h and subjected to polysomal fractionation. 
Fractions 6 to 10 were pooled (poly). In parallel, total RNA was isolated. Expression of mRNAs 
was tested by qPCR and normalized to GAPDH. Data are shown as fold inductions relative to 
Ctr. Values are mean values ± SEM, n > 3. 
 
Surprisingly, in contrast to the results of the microarray analysis, all of the 8 tested 
mRNAs changed in expression not only on polysomal but also on total RNA level upon 
CM treatment (Figure 5-5). CBLB, GFRA2, vitamin D receptor (VDR), alpha-amylase 1A 
(AMY1A)  and  cluster  of  differentiation  (CD44)  changed  on  both  levels  to  a  similar 
extend  and  therefore  have  to  be  considered  to  be  predominantly  transcriptionally 
regulated. Notably, PLAUR, EGR2 and cytochrome P 24A1 (CYP24A1) showed higher 
changes  in  the  polysomes  than  in  total  RNA,  thus  indicating  an  upregulation  on 
transcriptional as well as on translational level.  
In order to investigate the translational changes of EGR2, PLAUR and CYP24A1 in more 
detail, I conducted polysomal fractionation with CM and Ctr treated MCF7 cells and 
analyzed the distribution of the target mRNAs in single fractions relative to total RNA 
within the whole gradient.  
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Figure 5-6: Distribution of mRNAs in single fractions 
MCF7 cells were treated with CM or Ctr for 4 h and subjected to polysomal fractionation. RNA was 
isolated from single fractions and the distribution of mRNA in single fractions was measured relative to 
total RNA using qPCR with primers for GAPDH (A), EGR2 (B), CYP24A1 (C) and PLAUR (D). Data are 
representative for at least 3 experiments.  
 
The  mRNA  distribution  of  glyceraldehyde-3-phosphate  dehydrogenase  (GAPDH)  did 
not change when comparing Ctr to CM treatment, thus proving that CM did not induce 
a general change in translation (Figure 5-6A). For EGR2 mRNA distribution a dramatic 
drop in monosomal fractions 1 to 3 could be observed upon CM treatment, whereas it 
markedly increased in the polysomal fractions 6 to 10 (Figure 5-6B) indicating that the 
mRNA  moves  from  monosomes  to  polysomes.  The  mRNA  distribution  of  CYP24A1 
changed  in  a  similar  way  but  not  to  the  same  extend  as  EGR2  (Figure  5-6C),  i.e. 
CYP24A1 mRNA was more abundant in fractions 5 and 6 under control conditions and 
increased in fractions 7 to 10 after CM treatment. In contrast, I could not observe a 
consistent movement from monosomes to polysomes for PLAUR (Figure 5-6D). These 
data  indicate  that  EGR2  and  CYP24A1  translation  is  specifically  induced  under 
inflammatory conditions. 
In  further  experiments  I  concentrated  on  the  investigation  of  the  translational 
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5.2  Mechanism of EGR2 translation 
5.2.1  EGR2 translation is significantly upregulated upon CM 
First I wanted to check whether the translational upregulation of EGR2 was significant. 
To allow for statistical evaluation, the relative amount of GAPDH and EGR2 mRNA was 
analyzed in single fractions (Figure 5-7A). Then the ratio of CM to Ctr was calculated in 
each fraction (Figure 5-7B).  
 
Figure 5-7: Calculation of target mRNA distribution changes 
 (A) MCF7 cells were treated with CM (black diamonds, solid line) or Ctr (white squares, 
dashed line) for 4 h and subjected to polysomal fractionation. RNA was isolated from 
single fractions and was analyzed using qPCR. The mRNA distribution over the isolated 
fractions was calculated for GAPDH (left panel) and EGR2 (right panel). (B) The ratio of 
mRNA distribution of CM to Ctr was calculated to visualize stimulus-dependent changes. 
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Since the mRNA distribution of GAPDH did not change in response to CM, GAPDH 
distribution was chosen as normalization control (Figure 5-7C). 
Combining all experiments revealed that GAPDH mRNA distribution did not change 
(Figure 5-8A), whereas EGR2 mRNA significantly decreased in all monosomal fractions 
1 to 4 and increased in all polysomal fractions 6 to 10 (Figure 5-8B). Specifically, the 
mean EGR2 mRNA distribution across all polysomal fractions increased to 196 ± 13% 
relative to Ctr, thus supporting enhanced translation.  
 
 
Figure 5-8: EGR2 mRNA distribution significantly changes upon CM 
MCF7 cells were treated with CM or Ctr for 4 h and subjected to polysomal fractionation. Changes of 
mRNA distribution induced by CM relative to Ctr were analyzed using qPCR for GAPDH (A), EGR2 (B) and 
EGR3 (C). Data are presented as means ± SEM (n > 3, ***p < 0.001). EGR2 and EGR3 distributions are 
normalized to GAPDH distribution. Mean polysomal change (fractions 6 to 10) of EGR2 upon CM was 
calculated relative to Ctr. 
 
For control purposes, I determined changes in the mRNA distribution of the related 
EGR3,  which  was  not  identified  to  be  translationally  regulated  in  the  microarray 
analysis.  As  expected  no  significant  changes  could  be  observed  for  EGR3  mRNA 
distribution in response to CM (Figure 5-7C). These data again demonstrate that EGR2 
translation is specifically induced under inflammatory conditions. 
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5.2.2  Impact of IL-1β and IL-6 on EGR2 translation 
Next,  I  wanted  to  identify  which  factor(s)  in  CM  account  for  the  translational 
upregulation of EGR2. 
 
5.2.2.1  Blocking IL-1β but not IL-6 impairs EGR2 translation 
In  5.1.1.1  the  abundance  of  several  cytokines  in  Ctr  and  CM  was  already  shown. 
Besides others, IL-6 and IL-1β were identified to be elevated in CM compared to Ctr. As 
IL-6 and the IL-1β-related IL-1α were previously shown to play a role in the regulation 
of translation of certain target mRNAs (167, 168), I investigated the impact of these 
cytokines  on  EGR2  translation.  To  this  end,  I  depleted  IL-6  and  IL-1β  in  CM  by 
preincubating  CM  with IL-1β  or  IL-6  neutralizing  antibodies or  with  an  IgG  isotype 
control for 1 h at 37°C. MCF7 cells were incubated with the resulting CMs or Ctr for 4 h 
followed by polysomal fractionation. 
 
 
Figure 5-9: Impact of IL-6 or IL-1β on EGR2 translation 
CM was pre-treated with IgG control [5 µg/mL], neutralizing IL-1β antibody [5 µg/mL] (A) or neutralizing 
IL-6 antibody [5 µg/mL] (B) for 1 h at 37°C. Then MCF7 cells were incubated with the respective CMs for 
4  h,  followed  by  polysomal  fractionation.  Changes  of  EGR2  mRNA  distribution  induced  by  CM+IgG 
compared to Ctr are shown in black bars, those induced by CM+αIL-1β are shown in orange bars and 
those induced by CM+αIL-6 are shown in green bars. Mean polysomal distribution (fractions 6 to 10) of 
EGR2 upon CM+αIL-1β or αIL-6 was calculated relative to CM+IgG. Data are presented as means ± SEM 
(n ≥ 3, *p < 0.05). 
 
In  response  to  the  IL-1β  depleted  CM,  EGR2  mRNA  distribution  to  the  polysomal 
fractions  was  lower  compared  to  the  IgG  control  CM  (Figure  5-9A).  Importantly, 
comparing polysomal fractions 6 to 10 of MCF7 cells treated with IL-1β-depleted CM Results                                                                                                                                           56 
with those treated with IgG control CM, revealed a significant decrease in the mean 
polysomal distribution of EGR2 to 86 ± 3%. 
In  contrast,  preincubation  with  neutralizing  IL-6  antibody  barely  changed  the 
translational induction by CM+IgG (Figure 5-9B). Pooling of polysomal fractions 6 to 10 
decreased the polysomal distribution of EGR2 to 96 ± 3% of the control.  
These  findings  support  an  involvement  of  IL-1β  in  the  process  causing  enhanced 
translation of EGR2, whereas IL-6 seems not to be relevant. 
 
5.2.2.2  Recombinant IL-1β induces EGR2 translation 
To determine whether IL-1β induces EGR2 translation on its own, I treated MCF7 cells 
with recombinant IL-1β (50 ng/mL) for 4 h and conducted polysomal fractionation. 
Recombinant IL-1β caused a marked shift of EGR2 mRNA into the polysomes (Figure 
5-10).  Specifically,  mean  EGR2  mRNA  distribution  across  all  polysomal  fractions 
significantly increased in the polysomes to 164 ± 11% relative to the control. 
 
 
Figure 5-10: Impact of recombinant IL-1β on EGR2 translation 
MCF7 cells were treated with recombinant human IL-1β [50 ng/mL]  for 4 h followed by polysomal 
fractionation. IL-1β-induced changes in EGR2 mRNA distribution relative to Ctr were analyzed using 
qPCR and normalized to GAPDH. Mean polysomal changes (fractions 6 to 10) of EGR2 in response to 
rIL-1β were calculated relative to Ctr. Data are presented as means ± SEM (n ≥ 3, *p < 0.05). 
 
Taken  together,  these  data  strongly  suggest  that  IL-1β  suffices  to  induce  EGR2 
translation. Moreover, IL-1β appears to contribute to the induction of EGR2 translation 
in response to conditioned medium from activated monocyte-derived macrophages. 
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5.2.3  Impact of p38-MAPK on EGR2 translation 
Next, I aimed at understanding the signaling cascades linking EGR2 translation and 
IL-1β. 
 
5.2.3.1  p38-MAPK is activated in response to CM 
IL-1β is known to induce p38-MAPK signaling via phosphorylation of the latter (169). 
Accordingly, I found that p38-MAPK is rapidly, but transiently phosphorylated in MCF7 
cells  in  response  to  IL-1β  treatment  (Figure  5-11A).  Interestingly,  the  same 
phosphorylation pattern was observed upon treatment with CM, whereas Ctr did not 
affect phosphorylation, i.e. activation of p38-MAPK (Figure 5-11), thus proving that 
p38-MAPK is indeed activated upon CM treatment. 
 
 
Figure 5-11: CM induces phosphorylation of p38-MAPK 
MCF7 cells were treated for 15, 30 and 60 min with human recombinant IL-1β [50 ng/mL] (A) or CM and 
Ctr  (B).  Whole-cell  extracts  were  subjected  to  Western  analysis  and  probed  with  the  indicated 
antibodies. Blots are representative for at least 3 independent experiments. 
 
5.2.3.2  Inhibition of p38-MAPK impairs EGR2 translation 
In further experiments, I examined whether the activation of the p38-MAPK pathway 
accounts for enhanced translation of EGR2. Therefore, I treated MCF7 cells with CM in 
combination  with  the  p38-MAPK  inhibitor  SB203580  [10  µM]  and  performed 
polysomal fractionation. 
Inhibition of p38-MAPK increased EGR2 mRNA distribution in monosomal fractions and 
decreased  its  distribution  in  polysomal  fractions  as  compared  to  CM-treated  cells. 
Specifically, the mean distribution of EGR2 mRNA across all polysomal fractions 6 to 10 
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alone) (Figure 5-12A). Hence, CM-induced EGR2 translation is partially inhibited by 
blocking p38-MAPK activity. 
 
 
Figure 5-12: Inhibition of p38-MAPK impairs EGR2 translation  
(A) MCF7 cells were treated for 4 h with Ctr, CM alone (black bars) or in combination with SB203580 [10 
µM] (blue bars). Using polysomal fractionation und qPCR, changes of EGR2 mRNA distribution were 
analyzed relative to Ctr. Data were normalized to GAPDH. Mean polysomal change (fractions 6 to 10) of 
EGR2 upon CM+SB was calculated relative to CM. Data are presented as means ± SEM (n ≥ 3, **p < 
0.01). (B) MCF7 cells were treated for 15 min with Ctr and CM pre-treated with IgG or IL-1β neutralizing 
antibody as described before. Whole-cell extracts were subjected to Western analysis and probed with 
the indicated antibodies followed by densitometric analysis. Levels of phospho-p38 were normalized to 
total  p38  and  are  presented  relative  to  Ctr.  Blot  is  representative  for  at  least  3  independent 
experiments.  
 
To  verify  that  IL-1β  contributed  to  activation  of  p38-MAPK  in  response  to  CM,  I 
employed  again  CM  depleted  for  IL-1β  by  a  neutralizing  antibody  and  tested  the 
activation, i.e. phosphorylation status, of p38-MAPK using Western analysis. Indeed, 
neutralizing  IL-1β  attenuated  CM-induced  phosphorylation  of  p38-MAPK  (Figure 
5-12B). 
In  summary,  these  results  indicate  that  IL-1β  increases  EGR2  translation  in  a  p38-
MAPK-dependent manner.  
 
5.2.4  EGR2 is translated in an IRES-dependent manner 
As described in detail in 3.1.1, translation can be initiated in a cap-dependent or cap-
independent  manner,  for  example  via  IRES  elements.  Therefore,  I  aimed  at 
determining the mode of translation of EGR2 under inflammatory conditions. 
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5.2.4.1  In silico analysis of EGR2-5’UTR 
As translation of individual mRNAs is often regulated via their 5’UTRs (170), I first 
analyzed the 5’UTR of EGR2. The 5’UTR of EGR2 proved to be relatively long being 
composed of 326 nucleotides (Figure 5-13A).  
 
 
Figure 5-13: EGR2-5’UTR is long and highly structured 
(A) Sequence of human EGR2-5’UTR. (B) Predicted structure of the human EGR2-5’UTR using mfold. 
 
To determine potential structures within the 5’UTR of EGR2, I used the online software 
mfold for an in silico structure analysis (162), which predicted a secondary structure 
containing various loops with a minimal free energy of -89.40  kcal/mol (Figure 5-13B). 
As described in 3.1.3.1, a structure with a free-energy of −50 kcal/mol is suﬃcient to 
block  UTR  scanning  (25).  The  EGR2-5’UTR  can  therefore  be  considered  as  highly 
structured.  
These findings imply that the 5’UTR of EGR2 is presumably a target of regulational 
control. 
 
5.2.4.2  Rapamycin induces EGR2 translation 
Next,  I  tested  whether  inhibition  of  cap-dependent  translation  in  general  has  an 
impact on EGR2 translation. For this purpose, I treated MCF7 cells with the mTOR 
inhibitor rapamycin to inhibit cap-dependent translation.  
As expected, polysomal distribution of GAPDH increased in monosomal fractions and 
decreased in polysomal fractions in response to rapamycin, indicative for an mRNA 
being translated cap-dependently (Figure 5-14A). Therefore, GAPDH could not be used 
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translation of EGR2 appeared to be enhanced under these conditions, supporting a 
cap-independent mechanism of EGR2 translation (Figure 5-14B).  
 
 
Figure 5-14: Rapamycin leads to altered GAPDH and EGR2 translation 
MCF7 cells were treated with rapamycin [100 nM] for 4 h and subjected to polysomal fractionation. RNA 
from single fractions was isolated. GAPDH (A) and EGR2 (B) mRNA distribution was analyzed using qPCR. 
Data are not normalized and presented as means ± SEM (n = 3). 
 
Taken together, the long and structured 5’UTR as well as the enhanced translation 
under conditions of inhibited cap-dependent translation support the assumption that 
EGR2  mRNA  might  be  translated  in  a  cap-independent,  e.g.  in  an  IRES-dependent 
manner. 
 
5.2.4.3  EGR2 contains an IRES element 
To  determine  if  an  IRES  element  is  present  within  the  5’UTR  of  EGR2,  I  used  the 
bicistronic  reporter  plasmids  pRF  and  phpRF  containing  both,  a  renilla  and  a 
downstream firefly luciferase gene. These constructs express renilla luciferase in a cap-
dependent manner, whereas the downstream firefly luciferase is only translated when 
a  functional  IRES  element  is  present  intercistronically  (Figure  5-15A).  In  addition, 
phpRF  contained  a  hairpin  sequence  that  was  inserted  upstream  of  the  renilla 
luciferase  open  reading  frame  to  minimize  cap-dependent  translation  and  inhibit 
reinitiation of translation (Figure 5-15B). To determine the presence of an IRES within 
the 5’UTR of EGR2, EGR2-5’UTR was inserted into the intercistronic regions of pRF and 
phpRF, resulting in pR-EGR2-F and phpR-EGR2-F, respectively.  
Cells  transiently  transfected  with  pRF  or  pR-EGR2-F  in  combination  with  the 
β-Galactosidase transfection control showed similar relative renilla activities (Figure 
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of EGR2-5’UTR (11.79 ± 2.27 fold relative to pRF). The same is true for the hairpin 
containing construct where I observed a 7.12 ± 0.61 fold induction of firefly luciferase 
compared  to  phpRF,  whereas  the  renilla  activity  remained  at  equal  levels  (Figure 
5-15B).  
 
 
Figure 5-15: Identification of an IRES element in the 5’UTR of EGR2 
Scheme of bicistronic  constructs pRF (A) and phpRF  (B)  used for reporter assays.  Vectors were  co-
transfected with SV40-β-Gal plasmid into MCF7 cells. 24 h after transfection renilla and firefly activities 
were measured and normalized to β-Galactosidase activity. Data are presented as means ± SEM (n > 3, 
**p < 0.01) relative to the empty vector. 
 
The  identification  of  IRES  elements  has  been controversially  discussed  in  literature 
(171), thus, it is crucial to exclude false positive identification of IRES elements that 
could arise from cryptic promoter activity or cryptic splicing. 
In an attempt to rule out cryptic promoter activity, I introduced the EGR2-5’UTR into 
the promoterless pGL3-basic vector, resulting in pGL3-EGR2.  
Insertion of EGR2-5’UTR did not enhance firefly activity in transiently transfected MCF7 
cells compared to the pGL3-basic parent vector (Figure 5-16A). The positive control 
containing  an  SV40  promoter  referred  to  as  pGL3-SV40  showed  a  strong  relative 
luciferase activity compared to the promoterless vector.  
As cryptic splicing events may cause the excision of the intercistronic region and/or the 
formation  of  fusion  proteins  that  exhibit  renilla  and  firefly  activities,  I  next  tested 
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Specifically, the full length transcript of the phpR-EGR2-F (R-EGR2-F) was predicted to 
contain 2933 nucleotides, whereas the phpRF control vector was expected to produce 
a transcript (RF) of 2587 nucleotides. For this purpose, I treated mRNA isolated from 
cells transfected with either phpRF or phpR-egr2-F with DNase to remove residual 
contaminations of the plasmid DNA. 
 
 
Figure 5-16: EGR2-5’UTR does not contain cryptic promoters or splice sites 
(A) MCF7 cells were co-transfected with the indicated reporter constructs and SV40-renilla plasmid. 48 h 
after transfection firefly activity was measured and normalized to renilla activity. Data are presented as 
means ± SEM (n > 3). (B) RNA isolated from cells transfected with phpRF or phpR-EGR2-F was DNase 
treated. cDNA was synthesized and PCR was performed with specific primers to amplify full length RL or 
R-EGR2-L mRNAs. PCR products were visualized via agarose gel electrophoresis. Data are representative 
for at least 3 independent experiments. (C) In vitro transcribed mRNA of the indicated reporter plasmids 
was transfected into MCF7 cells. 24 h after transfection renilla and firefly activities were measured. Data 
are presented as means ± SEM (n > 3, **p < 0.01) relative to hpRF. 
 
PCR with primers that specifically bind to the 5’end of renilla and 3’end of firefly open 
reading frames to amplify the full length RL or R-EGR2-L mRNAs resulted in a single 
product of the expected size for each vector (Figure 5-16B).  
Finally, I used in vitro transcribed, capped mRNA instead of DNA for transfection of the 
indicated  constructs  to  exclude  any  cryptic  promoter  or  splicing  events  since 
transfected  mRNA  does  not  enter  the  nucleus  where  splicing  occurs.  While  renilla 
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± 0.83 fold when comparing hpR-egr2-F mRNA to hpRF mRNA (Figure 5-16C). 
These  data  strongly  support  the  presence  of  a  functional  IRES  element  within  the 
5’UTR of EGR2. 
 
5.2.4.4  Localization of the EGR2-IRES element within the 5’UTR 
To  determine  the  exact  localization  of  the  IRES  element  within  the  EGR2-5’UTR,  I 
cloned deletion constructs containing different fragments of the 5’UTR and inserted 
them into the bicistronic reporter construct. These constructs were transfected into 
MCF7 cells and the IRES activity was measured by calculating the ratio of firefly to 
renilla luciferase activities (Figure 5-17).  
 
 
Figure 5-17: Full length EGR2-5’UTR is required for full IRES activity 
The deletion constructs II to IV of the EGR2-5’UTR were inserted into the bicistronic reporter plasmid as 
indicated and transfected into MCF7 cells. IRES activity was calculated as ratio of firefly luciferase to 
renilla luciferase and is given relative to construct I (full length EGR2-5’UTR). Data are presented as 
means ± SEM (n > 3, *p < 0.05, **p < 0.01). 
 
While the reduction of EGR2-IRES activity of construct III to 82 ± 15% of the full length 
construct I was not significant, insertion of the constructs II and IV led to a significant 
decrease  of  EGR2-IRES  activity  down  to  62  ±  10%  and  64 ± 7%  of  the  full  length. 
However, from these constructs it was not reasonable to define a specific region in the 
5’UTR that is responsible for the IRES activity. Thus, I assume that the entire 5’UTR of 
EGR2 appears to be necessary for maintaining full IRES activity. 
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5.2.4.5  CM and IL-1β induce EGR2-IRES activity p38-MAPK-dependently 
In the following experiments, I determined whether the IRES element of EGR2 also 
responds to CM. For this purpose, I transfected the hairpin containing phpR-EGR2-F 
construct into MCF7 cells and treated them for 24 h with CM or Ctr. As predicted, IRES 
activity of phpR-EGR2-F transfected cells was significantly induced in response to CM 
up to 2.30 ± 0.22 fold compared to Ctr (Figure 5-18A). 
 
 
Figure 5-18: CM and IL-1β enhance EGR2-IRES activity 
MCF7 cells were transfected with phpR-EGR2-F and treated with Ctr or CM for 24 h (A), with Ctr, CM or 
rIL-1β [50 ng/µL] for 4 h (B) or for 4 h with CM or CM containing SB203580 [10 µM] (C). EGR2-IRES 
activity was calculated as ratio of firefly luciferase to renilla luciferase. Data are presented as means ± 
SEM (n > 3, *p < 0.05, **p < 0.01). 
 
In the next set of experiments, I aimed at determining if the CM-induced IRES activity 
was also dependent on IL-1β and p38-MAPK activation. To this end, cells were again 
transfected with phpR-EGR2-F. As seen in (Figure 5-18B), treatment with CM for 4 h 
led to a significant 1.5 ± 0.18 fold increase of EGR2-IRES activity. Similarly, treatment 
with recombinant IL-1β alone resulted in a 1.34 ± 0.11 fold IRES activation compared to 
Ctr treated cells. Importantly, CM-induced IRES activity was significantly reduced by 
the p38-MAPK inhibitor SB203580 to 82 ± 4% (Figure 5-18C). 
Thus,  I  conclude  that  within  an  inflammatory  environment,  IL-1β  and  p38-MAPK 
contribute to EGR2-IRES-dependent translation. 
 
5.2.5  Various ITAFs bind to the 5’UTR of EGR2  
As  described  in  3.1.3.3,  IRES-dependent  translation  commonly  requires  IRES  trans-
acting factors (ITAFs) that bind to the mRNA to recruit initiation factors and ribosomal Results                                                                                                                                           65 
subunits to the mRNA. Therefore, I wanted to identify factors that bind to the 5’UTR of 
EGR2. 
 
5.2.5.1  Identification of proteins that bind to EGR2-5’UTR 
To detect proteins bound to RNAs, the method of streptavidin-tethered RNA-affinity 
purification is commonly used. For this purpose, I transcribed the 5’UTR of EGR2 in 
vitro  and  conjugated  a  biotin-label  at  the  5’end.  This  labeled  transcript  was  then 
incubated with streptavidin agarose beads and protein lysates of CM-treated MCF7 
cells. After elution and electrophoretic separation, proteins bound to the 5’UTR of 
EGR2  were  visualized  by  silver  staining  (Figure  5-19A)  and  analyzed  by  mass 
spectrometry  in  cooperation  with  the  Molecular  Bioenergetics  Group  (Faculty  of 
Medicine, Frankfurt). 
 
 
Figure 5-19: Identification of proteins that bind to EGR2-5’UTR 
(A) Lysates of CM-treated MCF7 cells were incubated with in vitro transcribed, biotinylated EGR2-5’UTR. 
After immunoprecipitation using streptavidin agarose beads, bound proteins were separated via SDS-
PAGE and visualized using silver  staining. Individual proteins  were identified by mass spectrometric 
analysis of gel  slices. Positions of identified proteins are shown on the  left side, protein molecular 
weight markers are shown on the right side. (B) Overview of selected targets that bound to EGR2-5’UTR 
identified by mass spectrometry  
 
Figure 5-19B lists selected targets that were identified by mass spectrometry and that 
were previously described to be involved in translational control (full list see section 8). 
A number of hnRNPs and initiation factors were identified to bind to the 5’UTR of 
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Interestingly,  among  the  EGR2-5’UTR-binding  proteins,  I  found  PTB  and  hnRNP-A1, 
which were previously shown to act as ITAFs associated with enhanced translation of 
target mRNAs (38, 40, 172).  
 
To ensure a RNA specific binding of these proteins to the EGR2-5’UTR, the interaction 
was  further  verified  via  RNA-affinity  purification  followed  by  Western  analysis 
including a control RNA of similar length (300 nucleotides) encoding human reverse 
GAPDH (hrG). Indeed, PTB, hnRNP-A1 and HuR bound to EGR2-5’UTR but not to the 
control (Figure 5-20A). Thus, I can ascertain a specific binding of these proteins to the 
EGR2-5’UTR but not to other RNAs. However, I could not observe a differential binding 
when comparing CM and Ctr treated MCF7 lysates (Figure 5-20B). 
 
 
Figure 5-20 Specific binding of ITAFs to EGR2-5’UTR 
(A) Lysates of CM-treated MCF7 cells were incubated with in vitro transcribed, biotinylated EGR2-5’UTR 
or human reverse GAPDH (hrG) RNA, before immunoprecipitation of proteins using streptavidin agarose 
beads. Bound proteins were subjected to Western analysis and probed with the indicated antibodies. 
Blots are representative for at least 3 independent experiments. (B) Lysates of Ctr or CM-treated MCF7 
cells were incubated with in vitro transcribed, biotinylated EGR2-5’UTR before immunoprecipitation of 
proteins  using  streptavidin  agarose  beads.  Bound  proteins  were  subjected  to  Western  analysis  and 
probed  with  the  indicated  antibodies.  For  whole  cell  lysates  10%  of  input  was  used.  Blots  are 
representative for at least 3 independent experiments.  
  
These data provide evidence that several ITAFs indeed bind to the 5’UTR of EGR2, 
which might influence the EGR2-IRES activity. 
 
5.2.5.2  Overexpression of hnRNP-A1 enhances EGR2-IRES activity 
Since hnRNP-A1 was identified to bind to the 5’UTR of EGR2 and it is already known to 
act as an ITAF, I wanted to test whether overexpression of hnRNP-A1 is sufficient to 
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dominant  negative  form  of  hnRNP-A1  (A1-NLS)  were  transiently  overexpressed  in 
phpR-EGR2-F transfected MCF7 cells and the IRES activity was measured. 
Overexpression of A1-WT led to a significant 1.8 ± 12 fold upregulation of EGR2-IRES 
activity compared to the empty vector control (EV), whereas the dominant-negative 
form of A1, which is supposed to inhibit endogenous hnRNP-A1 by sequestration to 
the nucleus, significantly decreased the IRES activity to 0.79 ± 12 fold of the empty 
vector (Figure 5-21A). Overexpression of the constructs was confirmed by Western 
analysis (Figure 5-21B).  
 
 
Figure 5-21: hnRNP-A1 overexpression leads to enhanced EGR2-IRES activity 
MCF7 cells were co-transfected with phpR-EGR2-F and pcDNA3.1 (EV), wildtype hnRNP-A1 (A1-WT) or 
dominant  negative  hnRNP-A1  (A1-NLS).  48  h  after  transfection  cells  were  harvested  and  luciferase 
activities were measured. IRES activity was calculated as described before and is given relative to EV. 
Data are presented as means ± SEM (n > 3, *p < 0.05, **p < 0.01). (B) MCF7 cells were transfected with 
the indicated constructs. Whole-cell extracts were generated, subjected to Western analysis and probed 
with the indicated antibodies. Blot is representative for at least 3 independent experiments. 
 
From these data I conclude, that EGR2 contains an IRES element within its 5’UTR which 
can be activated by inflammatory stimuli dependent on p38-MAPK activity and hnRNP-
A1 availability, in turn enhancing translation of EGR2. 
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6  Discussion 
Translation  is  a  sophisticated  and  tightly  regulated  process  that  enables  post-
transcriptional  control  of  gene  expression.  The  regulation  of  translation  offers  the 
possibility of a rapid response to external stimuli, without invoking nuclear pathways 
for  mRNA  synthesis,  processing  and  transport.  Besides,  given  the  huge  amount  of 
energy needed for protein synthesis (2 ATP and 2 GTP molecules per each peptide 
bond, see 3.1) it is pivotal to monitor this process.  
The essential idea of translational control is that gene expression is regulated by the 
efficient use of one mRNA strand for protein synthesis. This may take place at multiple 
levels, which include targeting of structural features of the mRNA, stimulating trans-
acting protein or RNA factors or modulating the activity of the translational apparatus 
all of which mostly affect translation initiation. While these processes are triggered by 
a  variety  of  stimuli  including  mitogens,  hormones,  nutrients  and  stress  signals, 
especially in the context of cancer progression (23, 173-175), little is known about the 
effect of inflammatory mediators on translational regulation. It is widely accepted that 
an inflammatory microenvironment is an essential component of tumors (176) and can 
be used in cancer immunotherapy to augment the response to chemotherapy (177, 
178).  However,  in  some  cases,  inflammation  can  diminish  the  beneficial  effects  of 
therapy (179). Therefore, it is crucial to understand regulatory mechanism at all levels 
– including translation – caused by inflammatory signals in tumor cells. To this end the 
present  study  aimed  at  identifying  translationally  deregulated  targets  during 
inflammation-associated  tumorigenesis.  In  depth  analysis  of  the  regulation  of  one 
specific target – EGR2 – provides information about a potential general strategy for 
regulating protein levels. 
 
6.1  Validation of the in vitro cell system 
The first task of the project was to establish an in vitro cell system that mimics the 
situation of tumor cells that are exposed to an inflammatory microenvironment. For 
this purpose, I used human U937 monocytes that were differentiated to macrophages 
by TPA treatment. U937 is a histiocytic lymphoma cell line that is widely used for the 
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inflammation  (180,  181).  To  ensure  that  U937  cells  generate  an  inflammatory 
environment in my setting, CBA analysis of the supernatant of differentiated U937 cells 
(CM)  was  performed.  Indeed,  of  the  six  cytokines  tested,  the  pro-inflammatory 
cytokines TNFα, IL-6, IL-8 and IL-1β and the anti-inflammatory cytokine IL-10 were 
significantly  elevated  compared  to  supernatants  of  undifferentiated  cells  (Ctr), 
whereas IL-12p70 could not be detected in both supernatants. Thus, it was proven that 
U937 cells secrete pro- and anti-inflammatory mediators and that the secretion profile 
changes after differentiation. Since only one timepoint was tested, i.e. 24 h after 48 h 
differentiation, it is not clear whether these cytokines show different concentrations 
after  shorter  or  longer  incubation  times  due  to  altered  expression  or  stability.  To 
clarify the exact type of macrophage generated upon TPA-treatment of U937 cells, in 
depth analysis of the secretion and surface marker profiles would be required.  
For the investigation of translational changes in tumor cells, the breast cancer cell line 
MCF7 was chosen. Breast cancers are highly infiltrated by macrophages which often 
correlates  with  poor  prognosis  (182).  Moreover,  MCF7  cells  are  estrogen  receptor 
positive  indicating  that  their  invasive  potential  is  only  moderate  as  the  estrogen 
receptor is often lost during tumor progression (183). This provided the opportunity to 
investigate changes in the tumorigenic potential. Indeed, I could show that CM has a 
pro-tumorigenic  impact  on  MCF7  cells,  since  it  induced  the  activity  of  the 
transformation  marker  AP-1,  which  is  a  dimeric  transcription  factor  complex  that 
regulates genes involved in cell proliferation, differentiation, apoptosis, angiogenesis 
and tumor invasion (184). In line, enhanced migration could be observed. Additionally, 
it  was  shown  previously  that  CM  strongly  reduces  protein  levels  of  the  tumor 
suppressor PDCD4 (185, 186). Taken together, these data indicate that CM induces a 
pro-tumorigenic  program  in  MCF7  cells.  Further  support  for  this  conclusion  comes 
from  the  microarray  analysis  of  total  RNA  from  4  h  CM-treated  compared  to  Ctr-
treated MCF7 cells. Pathway analysis revealed that pro-tumorigenic and anti-apoptotic 
networks were activated. Moreover, a strong inflammatory response was induced in 
MCF7 cells. 
To identify those genes, which are regulated on the translational level, I conducted 
microarray analysis of polysome-bound mRNA. The polysomal mRNA is that portion of 
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average, ribosomes appear once every 80-100 nucleotides with a limit of one per 30–
40  nucleotides  due  to  packing  constraints  (187).  The  more  ribosomes  bind  to  the 
mRNA, the more efficient is the translation and the more protein is synthesized from 
one  mRNA  strand.  In  order  to  isolate  polysome-bound  mRNA  the  technique  of 
polysomal fractionation was used, which involves the separation of the mRNA on a 
sucrose gradient according to its sedimentation after ultracentrifugation. This method 
is the most flexible and powerful tool for diagnosing and investigating translational 
changes.  For  global  identification  of translational  changes,  the  polysomal  RNA  was 
pooled and analyzed using microarray. Due to the fact that mRNAs that change in 
abundance, that is for example via enhanced transcription, are expected to similarly 
increase in the polysomes and monosomes, the results of the total RNA changes were 
compared  with  the  polysomal  changes.  In  fact,  only  those  genes  that  showed  a 
stronger  change  in  the  polysomes  than  on  total  RNA  level  were  considered  to  be 
translationally regulated. 42 targets were found to meet these criteria. Some of them 
were already shown to be subject to post-transcriptional regulation such as CYP24A1 
(188), PLAUR (189) and CD44 (190). Validation of 8 selected targets confirmed the 
microarray results.  
To take a closer look on the translational status of specific mRNAs, I analyzed their 
distribution in single fractions. When translation initiation is enhanced the polysomes 
become  larger  (=  more  ribosomes  per  mRNA  →  more  mRNA  abundant  in  later 
fractions). The same is true in the case of elongation inhibition, since initiation still 
occurs normally and the ribosomes accumulate at the mRNA, thereby shifting it to 
later fractions within the polysomes.  
To distinguish an increase in translation initiation from a decrease in elongation, the 
amount of mRNA in the subpolysomes, which are presented by nonactive mRNPs and 
monosomes, has to be considered. If an mRNA does not shift within the polysomes but 
from  subpolysomal  to  polysomal  fractions,  translation  initiation  is  enhanced.  This 
applied to the mRNA distribution change of EGR2 that showed the highest change in 
polysomes, hence, this target was chosen for further investigation. 
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6.2  Involved pathways of EGR2 translation 
So  far  regulation  of  EGR2  is  only  poorly  understood.  Some  studies  suggested 
transcriptional activation for EGR2. The most prominent transcription factor identified 
to date is NF-AT, which induces EGR2 expression during T cell anergy induction (122). 
p53  has  also  been  described  to  directly  bind  to  the  EGR2  promotor  to  induce  its 
transcription (151). A recent report identified miR-17-92 to bind to the 3’UTR of EGR2 
and to reduce EGR2 levels in murine macrophages during leukemogenesis (155). The 
authors assume this effect was either caused by enhanced destabilization of EGR2 
mRNA or decreased translation, yet without experimental verification. However, by 
use  of  polysomal  fractionation,  I  could  prove  that  EGR2  translation  is  significantly 
enhanced  in  breast  cancer  cells  that  are  challenged  with  a  pro-inflammatory 
microenvironment generated by CM. This effect was at least in part mediated by IL-1β 
that is present in CM. Notably, depletion of IL-1β via neutralizing antibodies did not 
fully  repress  and,  similarly,  treatment  with  recombinant  IL-1β  did  not  completely 
recover induction of EGR2 translation compared to CM. Therefore, it is likely that other 
factors might contribute to the induction of EGR2 translation as well. I additionally 
tested the effect of neutralizing IL-6 in CM but only a minimal inhibition could be 
observed.  It  would  be  of  great  interest  to  examine  whether  simultaneous 
neutralization  of  IL-1β,  IL-6  and/or  other  cytokines  acted  synergistically  on  EGR2 
translation. 
Since IL-1β is known to induce phosphorylation and thereby activation of p38-MAPK 
(169,  191),  I  assessed  the  p38-MAPK  activity  in  my  system.  I  observed  strong 
phosphorylation  of  p38-MAPK  upon  CM  or  IL-1β  treatment  after  15  min  already 
whereas Ctr had no effect. This effect was transient, i.e. phosphorylation decreased 
again after 30 min and was back to control levels after 1 h. In line, neutralization of 
IL-1β  in  CM  diminished  p38-MAPK  phosphorylation,  thereby  verifying  that  IL-1β  is 
responsible  for  the  CM-induced  p38-MAPK  activation.  To  determine  whether  p38-
MAPK activation also accounts for EGR2 translation, I used the p38-MAPK inhibitor 
SB203580  in  polysomal  fractionation  experiments  (192).  I  observed  a  significant 
decrease of EGR2 translation when p38-MAPK was inhibited, thus proving that p38-
MAPK contributes to the translational activation of EGR2. Notably, translation of EGR2 
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1 h CM treatment already. This discrepancy may be due to the fact, that while p38-
MAPK activation is typically transient, various downstream signaling events might be 
required until EGR2 translation is activated. Again p38-MAPK inhibition could not fully 
inhibit EGR2 translation, implying the involvement of additional signaling pathways in 
this process. 
 
6.3  IRES-dependent EGR2 translation 
While  IL-1β  was  previously  shown  to  suppress  IRES-dependent  translation  of 
thrombomodulin (193), no translation-inducing function of IL-1β has been identified so 
far. Recently, IL-1α was reported to activate translation of mRNAs such as IκBζ and IL-6 
(168).  Moreover,  IRES-dependent  translation  of  pro-survival  genes  like  cMyc  was 
shown  to  be  p38-MAPK-dependent,  which  was  activated  by  IL-6  (194,  195).  IRES-
dependent  translation  is  often  activated  under  stress  situations  such  as  nutrient 
deprivation and hypoxia when mTOR and subsequently cap-dependent translation is 
repressed (32). Interestingly, I observed enhanced EGR2 translation upon rapamycin-
treatment, which is a specific mTOR inhibitor (196). Thus, I concluded that an IRES-
dependent mechanism may account for EGR2 translation. In order to identify IRES 
elements within the 5’UTR of target mRNAs, bicistronic reporter plasmids were used 
(referred to as phpRF and phpR-EGR2-F), which contain two ORFs and the 5’UTR of 
interest inserted in between. Specifically, the potential IRES element is flanked by an 
upstream  renilla  luciferase,  which  is  translated  cap-dependently,  whereas  the 
downstream firefly luciferase can only be translated when an IRES element is located 
intercistronically to induce translation internally (30). The plasmid used in this study 
additionally  contained  a  hairpin  structure  generated  by  a  palindromic  sequence 
upstream  of  the  renilla  luciferase  to  reduce  cap-dependent  translation  and  read-
through  across  the  renilla  termination  codon.  Insertion  of  the  EGR2-5’UTR  indeed 
resulted  in  a  strong  induction  of  firefly  activity  indicating  an  IRES-dependent 
mechanism of translation. This finding was also supported by the fact that CM and 
IL-1β-treatment  induced  IRES  activity  while  inhibition  of  p38-MAPK  reduced  it. 
Notably, all effects that were observed via polysomal fractionation and subsequent 
analysis  of  EGR2  mRNA  distribution  were  also  observed  when  testing  EGR2-IRES 
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The use of bicistronic reporter plasmids for the identification of IRES elements has 
been questioned because of the potential presence of cryptic promoters or splice sites 
within 5’UTRs, which may lead to firefly expression from a monocistronic mRNA (171). 
Cryptic splicing is of special interest since the renilla luciferase contains a splice donor 
site which might induce splicing events when the inserted 5’UTR contains a suitable 
splice acceptor site (197). Indeed, an accurate re-examination of some predicted IRES 
containing sequences such as XIAP revealed that their first identification might have 
been false-positive due to the generation of aberrant monocistronic transcripts (198). 
However, the occurrence of cryptic splicing or promoter activities does not necessarily 
exclude the presence of IRES elements. Sherill et al. could prove that while the Bcl2-
5′UTR contains both an alternatively spliced intron and a minor promoter, an IRES 
element  was  still  attributable  to  enhanced  translation  of  Bcl2  (199).  Therefore, 
stringent test procedures are required to clarify this issue. One unequivocal proof of 
principle is the transfection of in vitro transcribed mRNA from the bicistronic reporter 
plasmid  (200).  Since  transfected  mRNA  does  not  enter  the  nucleus  it  is  neither 
transcribed nor spliced. Transfection of hpR-EGR2-F mRNA led to even higher induction 
of firefly luciferase as compared to transfected DNA. Additionally DNase-treated RNA 
was  extracted  from  transfected  cells  and  cDNA  synthesized.  PCR  with  primers  to 
amplify the full length bicistronic mRNA revealed that shortened constructs, which 
might occur from cryptic splicing, were not present. Finally, EGR2-5’UTR was inserted 
into  the  promoterless  monocistronic  pGL3-basic  vector  and  transfected  into  MCF7 
cells. No induction of firefly activity could be observed, thus, cryptic promoter activity 
was  ruled  out.  These  important  control  experiments  clearly  excluded  that  cryptic 
promoters or splicing events accounted for the proposed EGR2-IRES activity in the 
bicistronic luciferase assays. Thus, I could unambiguously proof the presence of an IRES 
element within the 5’UTR of EGR2. 
 
6.4  Impact of ITAFs on EGR2 translation 
Cellular IRES-mediated translation is typically less efficient than the best studied cases 
of  viral  IRES-mediated  translation  (201).  However,  an  increasing  body  of  evidence 
indicates  that  cellular  IRESs  have  two  major  functions.  First,  they  support  robust 
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mitosis, when cap-dependent translation is compromised. Second, they support low 
levels of translation initiation for cellular IRES containing mRNAs with highly structured 
5’UTRs.  These  are  incompatible  with  efficient  scanning  under  normal  physiological 
conditions  when  cap-dependent  translation  is  fully  active  (202).  In  fact,  it  was 
previously shown that CM induces the PI3K-mTOR-pathway, thus proving that mTOR 
and  subsequent  cap-dependent  translation  is  not  generally  inhibited in  my  system 
(185). Accordingly, the translation efficiency of the housekeeping gene GAPDH does 
not change upon treatment with CM. Hence, I conclude that the activation of IRES-
dependent EGR2 translation mediated by CM is not due to the induction of stress 
signaling  pathways  that  generally  shut  down  cap-dependent  translation  thereby 
favoring  IRES-dependent  translation.  Instead,  induction  of  specific  factors  that 
facilitate EGR2 protein synthesis in an IRES-dependent manner appears rational.  
This is further corroborated by the observation that the 5’UTR of EGR2 is relatively 
long containing 326 nucleotides and highly structured as predicted by use of mfold, 
which calculated a secondary structure with a minimal free energy of -89.40 kcal/mol. 
A structure with a free-energy of -50 kcal/mol is sufficient to block UTR scanning and 
indicates the need for additional factors (25). Conventional scanning from the 5’end is 
not efficient for most IRES containing cellular mRNAs because their 5’UTRs are typically 
long, GC-rich and highly structured. Accordingly, the activity of cellular IRES elements 
strongly depends on the availability and interaction of their corresponding IRES trans-
acting factors (ITAFs). By use of RNA pulldown and subsequent mass spectrometry 
analysis  319  proteins  were  found  to  bind  to  the  5’UTR  of  EGR2.  Among  various 
translation  initiation  factors  as  well  as  heterogeneous  nuclear  ribonucleoproteins 
(hnRNPs) some previously described ITAFs were found namely PTB, hnRNP-A1 and 
HuR. Their binding to the EGR2-5’UTR was highly specific since pulldown with GAPDH 
RNA did not show an interaction with any of these proteins.  
Interestingly, overexpression of wildtype hnRNP-A1 significantly enhanced whereas a 
dominant  negative  form  (hnRNP-A1-NLS)  diminished  EGR2-IRES  activity.  The  NLS-
construct contains the bipartitebasic-type NLS of hnRNP-K fused in frame with the N-
terminus of an hnRNP-A1 mutant (A1-G274A), which lacks both nuclear import and 
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potential to compete with wild-type hnRNP-A1 for binding to and nuclear export of 
mRNAs thereby sequestering it to the nucleus (161). 
However,  I  could  not  observe  a  differential  expression  or  binding  affinity  when 
comparing CM- or Ctr-treated protein lysates indicating that CM does not alter hnRNP-
A1 protein levels. Yet, the mechanisms responsible for regulating ITAF concentration 
and  activity  have  not  been  fully  defined.  Several  studies  have  suggested  that  the 
subcellular distribution of ITAFs is an important determinant for IRES activity (202). 
Since whole cell lysates were prepared for the RNA pulldown and protein expression 
experiments, a difference in the localization of hnRNP-A1 would not have been taken 
into  consideration.  Moreover,  hnRNP-A1  has  been  shown  to  be  regulated  via 
phosphorylation of its M9 peptide domain by p38-MAPK which subsequently caused 
enhanced  IRES-dependent  translation  of  cMyc  (167,  194).  Whether  hnRNP-A1  is 
phosphorylated before it binds to its target mRNA or vice versa is not clear. Because of 
the lack of commercially available phospho-hnRNP-A1 antibodies the phosphorylation 
status of hnRNP-A1 was not determined. On account of the fact that the IRES activity 
of EGR2 is also dependent on p38-MAPK signaling, I conclude that phosphorylation 
and/or localization events of hnRNP-A1 are likely to be the mechanism of action for 
regulating the influence of hnRNP-A1 on the translation of EGR2. 
Besides hnRNP-A1, PTB was also found to bind to EGR2-5’UTR. This was not surprising 
given the fact that PTB is considered to be a general ITAF for most of the identified 
cellular IRESs so far (52). PTB plays a role in the recruitment of the ribosome to the 
mRNA (203). PTB often needs co-factors to bind to the 5’UTR such as poly(rC)-binding 
protein 1 (PCBP1) or upstream of N-ras (UNR) which cause a conformational change 
allowing PTB to bind and to recruit the ribosome (204, 205). Strikingly, PCBP1 was also 
identified by mass spectrometry to bind to the 5’UTR of EGR2 (see Table 8-3). The 
consensus  sequence  for  PTB-mediated  ribosome  recruitment  is  (CCU)n  (52). 
Interestingly, two CCU elements are located within the EGR2-5’UTR namely at position 
-258 and -69. The generation of different deletion constructs of the EGR2-5’UTR in the 
bicistronic vector with either the one or the other CCU deleted led to a reduction of 
the IRES activity for each construct but none of the two could completely abolish IRES 
activity.  Probably,  one  PTB-binding  site  is  sufficient  to  maintain  IRES  activity. 
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mutated  could  give  further  insights  into  the  impact  of  PTB  on  EGR2  translational 
regulation. Additionally, knockdown of PTB or hnRNP-A1 and subsequent polysomal 
fractionation could support the involvement of one or both of these factors in the 
ribosomal loading onto the EGR2 mRNA. 
The function of HuR on IRES activity is not clear, yet. While one report described HuR 
as an inducer of XIAP-IRES activity (100), another study proved its inhibitory potential 
on p27
Kip1-IRES activity (206). In line, IL-1β-mediated repression of thrombomodulin-
IRES activity was also mediated via enhanced binding of HuR (193). It was also shown 
that hnRNP-C competes with HuR for binding to the IGF-IR-5’UTR to enhance IRES-
mediated translation initiation (207). Whether HuR regulates the IRES activity of EGR2 
remains  to  be  elucidated  for  example  via  knockdown  and/or  overexpression 
experiments.  Interestingly,  Papadopoulou  et  al.  recently  described  a  complex 
comprising a number of hnRNPs and HuR to interact with mRNAs (208). Since many 
hnRNPs were identified to bind to the EGR2-5’UTR, changes in its binding complexes 
might account for the translational regulation of EGR2 as well. 
Figure 6-1: Mechanism of EGR2 translation 
Macrophages secrete cytokines such as IL-1β that induce a signaling cascade leading to p38-
MAPK induction and subsequent binding of ITAFs such as PTB or hnRNP-A1 to an IRES element 
within the 5’UTR of EGR2. IRES-dependent translation is induced and ribosomes are recruited 
to the mRNA to mediate protein synthesis. 
Abbreviations:  40S,  40S  ribosomal  subunit;  EGR2,  early  growth  response  2;  hnRNP, 
heterogeneous nuclear ribonucleoprotein; HuR, human antigen R; IL, interleukin; IRES, internal 
ribosome entry site; ITAF, IRES trans-acting factor;  mRNA, messenger ribonucleic acid;  p, 
phospho group; p38, p38 mitogen activated protein kinase; PTB, polyprimidine tract-binding 
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6.5  Therapeutic opportunities and concluding remarks 
Functionally,  EGR2  was  described  as  a  transcription  factor  belonging  to  the  early 
growth  response  gene family,  that  are  activated  immediately  after  serum  addition 
(113).  It  was  shown  to  be  crucial  for  hindbrain  development  (209)  and  recently 
proposed to exert E3 SUMO ligase activity (116). Furthermore, EGR2 was identified as 
an  important  regulator  of  T  cell  tolerance  by  inhibiting  IL-2  production,  thereby 
promoting a TCR-induced negative regulatory program. Its role in the regulation of cell 
proliferation is controversial. EGR2 was shown to be induced in cells overexpressing 
the tumor suppressor PTEN (149) implying anti-proliferative effects. On the opposite, it 
also appears to induce the anti-apoptotic protein Mcl1 and to stimulate proteasomal 
degradation of the pro-apoptotic protein Bim (153) denoting pro-survival functions. 
Thus, while EGR2 translation is enhanced under conditions which I and others have 
shown to be pro-tumorigenic (185, 186), the function of EGR2 in this setting remains to 
be elucidated. However, the proposed mechanism in this study for regulating EGR2 
protein levels may not be exclusive for MCF7 cells. In fact, it will be of utmost interest 
to  assess  whether  IRES-dependent  translation  of  EGR2  might  play  a  role  in  the 
induction of T cell anergy as well and if this mechanism could be relevant for clinical 
applications.  Regulating  T  cell  anergy  is  important  for  blocking  tumor-induced 
tolerance in cancers or during the immunosuppressive treatment of transplantation 
patients. With respect to the latter, cyclosporin A (CsA) is a potent clinically relevant 
immunosuppressive  agent  which  blocks  NF-AT  activation  by  inhibiting  calcineurin. 
Consequently, T cell activation is blocked. Thus, transplantation patients must remain 
on  CsA  therapy  indefinitely.  Unfortunately,  CsA  has  severe  side  effects  such  as 
nephrotoxicity  and  hepatotoxicity  (210).  Alternatively,  pharmacological  agents  that 
block T cell activation but leave EGR2 induction intact might have the added benefit of 
promoting T cell tolerance. The specific induction  of IRES-dependent translation of 
EGR2, for example via activation of p38-MAPK and/or hnRNP-A1, might support this 
effect. Interestingly, rapamycin is also in clinical use for transplantation patients with 
less side effects than CsA (211). As I could observe enhanced EGR2 translation upon 
treatment  with  rapamycin,  one  until  now  unknown  mechanism  of  exerting  its 
beneficial effects might be the induction of EGR2 translation thereby promoting T cell 
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evade tumor-induced immune tolerance (124). In this case, inhibition of factors that 
specifically  promote  EGR2  translation  might  be  advantageous,  such  as  chemically 
blocking p38-MAPK or neutralizing IL-1β, while at the same time leaving TCR-induced 
T cell activation intact. Notably, rapamycin is in clinical trial for cancer therapy as well 
(81). This might have the disadvantageous side effect of inducing EGR2 translation 
thereby facilitating T cell anergy. Therefore, co-treatment with compounds that inhibit 
EGR2 as mentioned above would be potentially required. 
Mutations  in  the  human  EGR2  gene  have  been  associated  with  peripheral 
myelinopathies, including Charcot-Marie-Tooth disease (CMT). Dominant neuropathy-
associated mutations of EGR2 have been identified in all three zinc fingers of the DNA-
binding domain and these mutations either result in decreased protein expression or 
impaired  DNA-binding  (142).  Interestingly,  mutations  in  the  5’UTR  of  Connexin  32 
(CX32) have also been linked to CMT. It was proven that CX32 contains an IRES whose 
function  is  abolished  after  insertion  of  a  mutation  resulting  in  reduced  protein 
synthesis  (212).  Up  to  now  the  identification  of  mutations  in  the  EGR2  gene 
concentrates  on  the  open  reading  frame  or  promoter  region.  In  the  light  of  the 
identified translational component of EGR2 regulation it might also be advisable to 
scan the 5’UTR for mutations in the future and check whether the IRES activity is 
affected. 
In summary, the presented data provide evidence for a novel mechanism of EGR2 
regulation  via  enhanced  IRES-dependent  translation  under  pro-inflammatory 
conditions.  This  effect  is  mediated  by  IL-1β  and  p38-MAPK  activation.  The  exact 
characterization and identification of missing signaling events, especially regarding the 
regulation of ITAF activity upon inflammatory stimuli, opens multiple opportunities for 
further studies. In depths analyses of the regulation of EGR2 will be of interest for 
conditions  where  T  cell  activation  should  be  therapeutically  altered  such  as 
transplantations or tumor immunotherapies. Moreover, the described mechanism may 
not be exclusive for one target but supports the understanding of regulation of gene 
expression in the context of inflammation-associated tumorigenesis. 
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Table 8-1: Proteins identified to bind to EGR2-5’UTR of CM lysates only by MS 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
O95433  AHSA1  9,17  2  2 
Q7L0Y3  MRRP1  8,93  2  2 
P55735  SEC13  6,83  2  2 
P24386  RAE1  1,99  2  1 
O95425  SVIL  1,13  2  1 
A4FU69  EFCB5  0,60  2  1 
 
Table 8-2: Proteins identified to  bind to EGR2-5’UTR of Ctr lysates only by MS 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
Q14258  TRI25  12,70  7  6 
Q07021  C1QBP  12,06  3  2 
Q9NSD9  SYFB  6,79  4  4 
P17987  TCPA  5,94  2  2 
P14618  KPYM  5,84  2  2 
O60506  HNRPQ  4,98  4  3 
P50990  TCPQ  4,56  2  2 
Q86VP6  CAND1  4,31  4  4 
P27694  RFA1  3,90  2  2 
P55060  XPO2  3,50  2  2 
Q8IXB1  DJC10  3,40  2  2 
Q9P2N5  RBM27  2,36  2  2 
Q92851  CASPA  1,34  11  1 
 
Table 8-3: Proteins identified to bind to EGR2-5’UTR of CM and Ctr lysates by MS 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
P07437  TBB5  71,62  199  26 
P68371  TBB2C  71,46  191  26 
P78347  GTF2I  68,54  329  67 
P60709  ACTB  66,67  121  22 
P68363  TBA1B  65,63  176  25 
Q71U36  TBA1A  62,53  171  23 
P04350  TBB4  59,91  120  19 
Q9BQE3  TBA1C  58,35  159  22 Appendices    94 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
Q13885  TBB2A  55,96  152  21 
Q12904  AIMP1  54,81  40  11 
Q15233  NONO  52,02  35  17 
P06748  NPM  51,70  71  13 
P26599  PTBP1  51,60  64  16 
Q96RQ3  MCCA  50,34  142  29 
P04792  HSPB1  49,27  21  6 
P50402  EMD  48,82  36  12 
P58107  EPIPL  48,57  248  84 
P11021  GRP78  46,64  62  26 
Q9HCC0  MCCB  45,65  55  20 
P10809  CH60  44,68  57  19 
P54136  SYRC  42,58  67  28 
Q9BRP8  WIBG  41,67  8  5 
Q13085  ACACA  41,39  304  79 
P42167  LAP2B  41,19  52  14 
P0CG47  UBB  40,61  31  3 
Q99623  PHB2  40,47  34  11 
P11498  PYC  39,90  135  38 
P68104  EF1A1  38,31  71  13 
P05198  IF2A  38,10  41  10 
P14868  SYDC  37,72  60  14 
P05166  PCCB  37,66  45  14 
P05165  PCCA  37,64  76  20 
Q15149  PLEC1  35,85  273  142 
P42166  LAP2A  35,16  59  19 
P25705  ATPA  35,08  31  14 
P35232  PHB  34,93  27  8 
Q15365  PCBP1  34,27  36  8 
P67809  YBOX1  34,26  11  5 
Q96AG4  LRC59  33,88  34  10 
P11142  HSP7C  33,13  81  20 
Q15046  SYK  32,50  60  20 
P23246  SFPQ  32,25  48  19 
P62258  1433E  32,16  14  7 
Q13509  TBB3  32,00  111  15 
P41091  IF2G  31,99  60  12 Appendices    95 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
P23396  RS3  31,69  12  6 
Q7KZF4  SND1  31,32  42  20 
Q13155  AIMP2  31,25  11  5 
Q9NY65  TBA8  30,73  50  9 
P61247  RS3A  30,68  14  8 
P52272  HNRPM  30,68  46  15 
P05388  RLA0  29,65  13  7 
P09429  HMGB1  28,37  10  7 
P36542  ATPG  27,85  16  7 
P07814  SYEP  27,78  62  32 
P31943  HNRH1  27,39  35  7 
P63104  1433Z  27,35  12  6 
P27348  1433T  27,35  6  5 
O14579  COPE  26,95  6  4 
P09651  ROA1  26,34  29  9 
Q9UMS4  PRP19  26,19  23  7 
Q9Y295  DRG1  25,61  25  7 
P08195  4F2  25,40  50  13 
P08238  HS90B  25,00  57  14 
P47897  SYQ  24,90  24  17 
P05141  ADT2  24,50  15  7 
P41252  SYIC  24,41  55  23 
Q14247  SRC8  24,00  18  10 
P61981  1433G  23,89  7  5 
Q86V81  THOC4  23,74  13  5 
P08865  RSSA  22,03  13  4 
Q12905  ILF2  21,79  12  5 
Q99729  ROAA  21,69  11  6 
Q04917  1433F  21,54  6  4 
P19338  NUCL  21,41  45  13 
P08107  HSP71  21,37  35  11 
O75534  CSDE1  21,18  26  14 
Q9Y446  PKP3  20,95  26  14 
Q9BUF5  TBB6  20,63  50  9 
Q96AE4  FUBP1  20,50  16  9 
Q14257  RCN2  20,19  20  5 
P51659  DHB4  20,11  17  10 Appendices    96 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
P06576  ATPB  20,04  12  7 
P17480  UBF1  20,03  23  11 
P04406  G3P  20,00  7  4 
Q8WXF1  PSPC1  19,89  16  9 
Q9NXA8  SIRT5  19,68  15  6 
P20042  IF2B  19,52  10  7 
P31946  1433B  19,51  5  4 
P48729  KC1A  19,29  7  5 
P15924  DESP  19,16  74  38 
P17844  DDX5  18,89  25  11 
Q92522  H1X  18,78  11  3 
P22626  ROA2  18,41  9  5 
P42704  LPPRC  18,29  33  19 
P02545  LMNA  18,07  20  9 
P22087  FBRL  17,76  7  4 
Q86UE4  LYRIC  17,53  19  7 
P07900  HS90A  17,49  38  10 
Q9P2J5  SYLC  17,35  27  15 
P00338  LDHA  17,17  15  5 
Q13283  G3BP1  17,17  12  5 
Q07666  KHDR1  17,16  8  4 
Q96CN7  ISOC1  17,11  6  4 
P06493  CDK1  16,50  4  4 
Q562R1  ACTBL  16,49  29  6 
Q92945  FUBP2  16,46  16  7 
Q14103  HNRPD  16,34  18  5 
P55795  HNRH2  16,26  11  4 
P11940  PABP1  16,19  13  7 
Q9BY44  EIF2A  15,90  9  6 
Q12849  GRSF1  15,63  6  4 
Q15366  PCBP2  15,34  28  4 
Q00577  PURA  15,22  3  2 
O95793  STAU1  15,08  8  6 
P09874  PARP1  14,79  20  11 
P52597  HNRPF  13,73  25  3 
Q01085  TIAR  13,33  5  3 
Q00839  HNRPU  13,33  9  6 Appendices    97 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
Q07065  CKAP4  13,29  7  5 
Q8NC51  PAIRB  12,99  4  3 
Q08211  DHX9  12,91  27  13 
O00165  HAX1  12,90  8  2 
P20700  LMNB1  12,63  5  4 
Q96P11  NSUN5  12,59  6  4 
Q13263  TIF1B  12,57  7  5 
Q12906  ILF3  12,42  18  10 
O95292  VAPB  12,35  4  2 
P49327  FAS  12,35  45  22 
P34931  HS71L  12,32  27  6 
Q15773  MLF2  12,10  5  2 
P04843  RPN1  12,03  8  5 
P63244  GBLP  11,99  11  3 
Q8WU90  ZC3HF  11,97  6  3 
P26583  HMGB2  11,96  5  3 
P18827  SDC1  11,94  3  2 
Q9H9B4  SFXN1  11,80  6  3 
O00571  DDX3X  11,78  18  6 
P13010  XRCC5  11,61  8  6 
P11387  TOP1  11,50  13  7 
Q9Y285  SYFA  11,42  5  3 
Q8WXX5  DNJC9  11,15  4  3 
O43175  SERA  11,07  6  5 
P19525  E2AK2  11,07  9  6 
P12268  IMDH2  10,89  4  3 
Q14008  CKAP5  10,88  22  17 
Q99459  CDC5L  10,85  10  6 
Q96I24  FUBP3  10,84  9  5 
Q13151  ROA0  10,82  3  2 
P16403  H12  10,80  9  2 
Q6ZRV2  FA83H  10,77  17  8 
Q8NE71  ABCF1  10,53  8  6 
Q01813  K6PP  10,46  8  6 
Q9NSI2  CU070  10,43  3  2 
Q96CT7  CC124  10,31  3  2 
P16401  H15  10,18  6  2 Appendices    98 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
P12956  XRCC6  10,02  5  4 
P17066  HSP76  9,95  19  5 
P52907  CAZA1  9,79  6  2 
P11586  C1TC  9,63  12  8 
P40939  ECHA  9,31  5  4 
P27824  CALX  9,29  7  4 
P32322  P5CR1  9,09  4  2 
P47755  CAZA2  9,09  5  2 
P62424  RL7A  9,02  4  2 
O60841  IF2P  9,02  19  7 
P47756  CAPZB  8,66  4  2 
P29692  EF1D  8,54  3  1 
Q9Y4P3  TBL2  8,28  3  2 
P09661  RU2A  8,24  3  2 
P02786  TFR1  8,16  8  5 
P61626  LYSC  8,11  36  1 
P26196  DDX6  8,07  3  2 
Q9BXS5  AP1M1  8,04  3  2 
Q5T3I0  GPTC4  7,85  4  2 
P61978  HNRPK  7,78  4  2 
P46109  CRKL  7,59  4  2 
P15927  RFA2  7,41  3  2 
Q9Y5M8  SRPRB  7,38  4  2 
Q3ZCQ8  TIM50  7,37  3  2 
Q15717  ELAV1  7,36  8  2 
P35250  RFC2  7,34  3  2 
Q9Y6Q5  AP1M2  7,33  4  2 
P12004  PCNA  7,28  2  1 
Q96PK6  RBM14  7,17  6  3 
O43290  SNUT1  7,12  4  3 
Q9BPW8  NIPS1  7,04  5  2 
Q9UJA5  TRM6  6,84  4  3 
P50750  CDK9  6,72  3  2 
Q01650  LAT1  6,71  4  2 
P23258  TBG1  6,65  3  2 
Q96HS1  PGAM5  6,57  5  2 
Q9BW19  KIFC1  6,54  5  3 Appendices    99 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
O15347  HMGB3  6,50  2  1 
Q16891  IMMT  6,46  5  3 
Q8WVV4  POF1B  6,45  5  3 
Q7Z2W4  ZCCHV  6,32  5  4 
P52292  IMA2  6,24  3  2 
Q9UN86  G3BP2  6,22  4  2 
Q14694  UBP10  6,02  4  3 
O43395  PRPF3  6,00  6  3 
O14979  HNRDL  5,95  8  3 
Q86XZ4  SPAS2  5,87  3  2 
Q08J23  NSUN2  5,87  4  3 
P33993  MCM7  5,84  3  3 
O00763  ACACB  5,82  50  11 
Q01844  EWS  5,79  6  2 
P17858  K6PL  5,77  5  3 
Q9UJS0  CMC2  5,63  6  3 
Q8NC56  LEMD2  5,57  3  2 
Q9UJV9  DDX41  5,31  3  2 
Q92499  DDX1  5,27  3  3 
P26641  EF1G  5,26  3  2 
Q9Y3F4  STRAP  5,14  2  1 
Q9HC36  RMTL1  5,00  3  2 
O43172  PRP4  4,98  3  2 
Q9Y3I0  CV028  4,95  4  2 
P62753  RS6  4,82  2  1 
Q14444  CAPR1  4,80  4  3 
Q13435  SF3B2  4,80  6  4 
O15446  RPA34  4,71  2  1 
Q00325  MPCP  4,70  6  2 
P18124  RL7  4,44  2  1 
Q9H3N1  TMX1  4,29  2  1 
P48634  BAT2  4,27  5  4 
P43243  MATR3  4,25  4  2 
P13639  EF2  4,20  4  3 
P51114  FXR1  4,19  3  2 
O43852  CALU  4,13  3  1 
Q9NVV4  PAPD1  4,12  3  2 Appendices    100 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
P05023  AT1A1  4,11  5  3 
P27816  MAP4  4,08  5  3 
P23771  GATA3  4,06  2  1 
O00338  ST1C2  4,05  2  1 
P49368  TCPG  4,04  4  2 
Q53H96  P5CR3  4,01  2  1 
O95817  BAG3  4,00  3  2 
P46940  IQGA1  3,98  6  4 
O00139  KIF2A  3,97  3  2 
P31153  METK2  3,80  3  1 
Q5T280  CI114  3,72  2  1 
P02768  ALBU  3,61  58  3 
P78527  PRKDC  3,59  16  13 
Q13724  MOGS  3,58  3  2 
P62701  RS4X  3,42  2  1 
P08237  K6PF  3,33  3  2 
Q15427  SF3B4  3,30  2  1 
Q6IN84  MRM1  3,12  2  1 
Q12907  LMAN2  3,09  3  1 
Q8N1G4  LRC47  3,09  2  1 
Q5T0W9  FA83B  3,07  3  3 
P14866  HNRPL  3,06  2  1 
P35637  FUS  3,04  3  1 
P27708  PYR1  2,79  6  4 
Q96EY1  DNJA3  2,50  2  1 
Q14157  UBP2L  2,21  4  2 
Q08379  GOGA2  2,20  3  2 
P49916  DNLI3  2,18  3  2 
Q9Y230  RUVB2  2,16  2  1 
Q8WXU2  DYXC1  2,14  5  1 
Q96SB4  SRPK1  2,14  2  1 
O94842  TOX4  2,09  2  1 
Q9ULX6  AKP8L  2,01  2  1 
P01833  PIGR  1,96  11  1 
P55084  ECHB  1,90  2  1 
Q92609  TBCD5  1,89  3  1 
Q00610  CLH1  1,85  3  2 Appendices    101 
AccessionNo.  Gene  ΣCoverage  #Hits  # Unique Peptides 
Q9BQG0  MBB1A  1,81  4  2 
Q92896  GSLG1  1,78  3  2 
P38646  GRP75  1,77  2  1 
Q9Y6X9  MORC2  1,74  4  2 
C9JN71  ZN878  1,69  38  1 
Q9HCD5  NCOA5  1,55  2  1 
Q99985  SEM3C  1,46  2  1 
P55265  DSRAD  1,22  2  1 
Q5D862  FILA2  0,96  7  2 
Q0VF96  CGNL1  0,77  3  2 
Q5S007  LRRK2  0,40  3  1 Publications    102 
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